<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Lancet Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Lancet Psychiatry</journal-id>
<journal-title-group>
<journal-title>The Lancet. Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">2215-0366</issn>
<issn pub-type="epub">2215-0374</issn>
<publisher>
<publisher-name>Elsevier Ltd.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31196793</article-id>
<article-id pub-id-type="pmc">7185541</article-id>
<article-id pub-id-type="publisher-id">S2215-0366(19)30190-7</article-id>
<article-id pub-id-type="doi">10.1016/S2215-0366(19)30190-7</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Catatonia and the immune system: a review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="au10">
<name>
<surname>Rogers</surname>
<given-names>Jonathan P</given-names>
</name>
<degrees>Dr</degrees>
<degrees>MBBChir</degrees>
<email>jonathan.rogers@kcl.ac.uk</email>
<xref ref-type="aff" rid="aff1">a</xref>
<xref ref-type="aff" rid="aff2">b</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author" id="au20">
<name>
<surname>Pollak</surname>
<given-names>Thomas A</given-names>
</name>
<degrees>Dr</degrees>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1">a</xref>
<xref ref-type="aff" rid="aff2">b</xref>
</contrib>
<contrib contrib-type="author" id="au30">
<name>
<surname>Blackman</surname>
<given-names>Graham</given-names>
</name>
<degrees>Dr</degrees>
<degrees>MBBS</degrees>
<xref ref-type="aff" rid="aff1">a</xref>
<xref ref-type="aff" rid="aff2">b</xref>
</contrib>
<contrib contrib-type="author" id="au40">
<name>
<surname>David</surname>
<given-names>Anthony S</given-names>
</name>
<degrees>Prof</degrees>
<degrees>FRCPsych</degrees>
<xref ref-type="aff" rid="aff3">c</xref>
</contrib>
<aff id="aff1"><label>a</label>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK</aff>
<aff id="aff2"><label>b</label>South London and Maudsley National Health Service Foundation Trust, Bethlem Royal Hospital, UK</aff>
<aff id="aff3"><label>c</label>Institute of Mental Health, University College London, London, UK</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>Correspondence to: Dr Jonathan P Rogers, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK <email>jonathan.rogers@kcl.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>6</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
<pub-date pub-type="ppub">
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>6</volume>
<issue>7</issue>
<fpage>620</fpage>
<lpage>630</lpage>
<permissions>
<copyright-statement>© 2019 Elsevier Ltd. All rights reserved.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Elsevier Ltd</copyright-holder>
<license>
<license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
</license>
</permissions>
<related-article ext-link-type="doi" id="d33e1080" related-article-type="article-reference" xlink:href="10.1016/S2215-0366(19)30212-3"></related-article>
<related-article ext-link-type="doi" id="d33e1083" related-article-type="article-reference" xlink:href="10.1016/S2215-0366(18)30474-7"></related-article>
<abstract id="ceab10">
<title>Summary</title>
<p>Catatonia is a psychomotor disorder featuring stupor, posturing, and echophenomena. This Series paper examines the evidence for immune dysregulation in catatonia. Activation of the innate immune system is associated with mutism, withdrawal, and psychomotor retardation, which constitute the neurovegetative features of catatonia. Evidence is sparse and conflicting for acute-phase activation in catatonia, and whether this feature is secondary to immobility is unclear. Various viral, bacterial, and parasitic infections have been associated with catatonia, but it is primarily linked to CNS infections. The most common cause of autoimmune catatonia is N-methyl-D-aspartate receptor (NMDAR) encephalitis, which can account for the full spectrum of catatonic features. Autoimmunity appears to cause catatonia less by systemic inflammation than by the downstream effects of specific actions on extracellular antigens. The specific association with NMDAR encephalitis supports a hypothesis of glutamatergic hypofunction in catatonia.</p>
</abstract>
</article-meta>
</front>
<body>
<p id="para210">This is the second in a <bold>Series</bold> of two papers on catatonia</p>
<sec id="cesec10">
<title>Introduction</title>
<p id="para220">Catatonia is a psychomotor disorder characterised by diverse clinical signs, including mutism, negativism, ambitendency, stereotypy, posturing, waxy flexibility, and echophenomena.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref> The structure and neural mechanisms of the disorder are reviewed elsewhere in this issue of <italic>The Lancet Psychiatry</italic> by Walther and colleagues.<xref ref-type="bibr" rid="bib2"><sup>2</sup></xref> Understanding the pathophysiology of this severe disorder is crucial given its high rate of medical complications, including pressure ulcers, infections, and venous thromboembolism.<xref ref-type="bibr" rid="bib3"><sup>3</sup></xref> Moreover, such understanding might aid the comprehension of other neuropsychiatric disorders.</p>
<p id="para230">Although catatonia has numerous possible symptom combinations,<xref ref-type="bibr" rid="bib4"><sup>4</sup></xref> compelling reasons to study it as a single entity exist. Clinical and demographic factors can distinguish catatonia from other psychotic and affective disorders.<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> Different forms of catatonia (retarded catatonia, malignant catatonia, and neuroleptic malignant syndrome) are highly comorbid.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref> In terms of treatment, response rates to benzodiazepines and electroconvulsive therapy (ECT) are high, regardless of the cause of the catatonia.<xref ref-type="bibr" rid="bib6"><sup>6</sup></xref> Moreover, catatonia is not a common disorder, so pragmatically, to study it in depth, considering it as a whole is useful.</p>
<p id="para240">Immune dysregulation is gaining interest as a pathophysiological mechanism underlying neuropsychiatric disorders as diverse as narcolepsy, some dementias, depression, and psychosis— with converging evidence from biochemical, neuroimaging, genetic, and postmortem studies.<xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib8">8</xref> Roles for both the innate immune system, which concerns the rapid, undirected response to pathogen-associated or injury-related signals, and the adaptive immune system, which functions over a longer timescale and involves the selection and maturation of antigen-specific T-cell and B-cell mediated responses, have been identified.</p>
<p id="para250">In this Series paper, we discuss the evidence for the involvement of the immune system in catatonia. This line of enquiry appears to be valuable, given the wide range of infective and inflammatory conditions that can cause catatonia (<xref ref-type="table" rid="tbl1">Table 1</xref>, <xref ref-type="table" rid="tbl2">Table 2</xref>
). We address whether the immune system has a role in catatonia, using some direct and some more circumstantial evidence, and endeavour to establish specific models. We consider immunity in terms of innate and adaptive systems for the purposes of clarity, while acknowledging that strictly demarcating the two is not always possible.<table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Systematic review of infective causes of catatonia</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th align="left"><bold>Cases (n)</bold></th><th align="left"><bold>Suspected organisms (cases, n)</bold></th></tr></thead><tbody><tr><td align="left">Bacterial meningitis or encephalitis</td><td align="left">5</td><td align="left"><italic>Borrelia burgdorferi</italic> (4), unspecified (1)</td></tr><tr><td align="left">Viral meningitis or encephalitis</td><td align="left">26</td><td align="left">Adenovirus (1), cytomegalovirus (1), coronavirus (1), Epstein–Barr virus (1), human herpesvirus 6 (1), herpes simplex virus (8), Japanese encephalitis virus (1), measles virus (2), tick-borne encephalitis virus (1), varicella-zoster virus (1), unspecified (9)</td></tr><tr><td align="left">Cerebral malaria</td><td align="left">2</td><td align="left"><italic>Plasmodium falciparum</italic> (1), unspecified (1)</td></tr><tr><td align="left">CNS infection unspecified</td><td align="left">3</td><td align="left">Unspecified (3)</td></tr><tr><td align="left">Respiratory tract infection</td><td align="left">10</td><td align="left">Influenza (1), Group A <italic>Streptococcus</italic> (2), <italic>Mycoplasma</italic> (1), <italic>Klebsiella</italic> (1), Epstein–Barr virus (1), unspecified (4)</td></tr><tr><td align="left">HIV-related</td><td align="left">22</td><td align="left">HIV (20), HIV and John Cunningham virus (2)</td></tr><tr><td align="left">Syphilis</td><td align="left">3</td><td align="left"><italic>Treponema pallidum</italic> (2)</td></tr><tr><td align="left">Systemic bacterial infection</td><td align="left">31</td><td align="left"><italic>Coxiella burnetti</italic> (1), <italic>Salmonella typhi</italic> (29), unspecified (2)</td></tr><tr><td align="left">Systemic viral infection</td><td align="left">4</td><td align="left">Cytomegalovirus (2), Epstein–Barr virus (1), flavivirus (1)</td></tr><tr><td align="left">Prion-related disorders</td><td align="left">7</td><td align="left">Prion protein (7)</td></tr><tr><td align="left">Other</td><td align="left">11</td><td align="left">Flavivirus vaccination (1), <italic>Tropheryma whipplei</italic> (1), <italic>Escherichia coli</italic> (1), <italic>Mycobacterium tuberculosis</italic> (1), <italic>Taenia solium</italic> (1), <italic>Chlamydia trachomatis</italic> (1), <italic>Trypanosoma cruzi</italic> (1), unspecified (4)</td></tr><tr><td align="left">Total</td><td align="left">124</td><td align="left">..</td></tr></tbody></table></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Systematic review of autoimmune causes of catatonia</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th align="left"><bold>Cases (n)</bold></th></tr></thead><tbody><tr><td align="left" colspan="2">Autoimmune thyroid disorders</td><td align="left">13</td></tr><tr><td></td><td align="left">Hyperthyroid state</td><td align="left">3</td></tr><tr><td></td><td align="left">Hypothyroid state</td><td align="left">4</td></tr><tr><td></td><td align="left">Euthyroid state with thyroid antibodies</td><td align="left">4</td></tr><tr><td></td><td align="left">Thyroid state not stated</td><td align="left">2</td></tr><tr><td align="left" colspan="2">Autoimmune encephalitis</td><td align="left">259</td></tr><tr><td></td><td align="left">GABA-AR encephalitis</td><td align="left">2</td></tr><tr><td></td><td align="left">NMDAR encephalitis</td><td align="left">249</td></tr><tr><td></td><td align="left">Progressive encephalomyelitis with rigidity and myoclonus</td><td align="left">1</td></tr><tr><td></td><td align="left">Voltage-gated potassium channel complex encephalitis</td><td align="left">4</td></tr><tr><td></td><td align="left">Unspecified</td><td align="left">3</td></tr><tr><td align="left" colspan="2">Demyelinating disorders</td><td align="left">13</td></tr><tr><td></td><td align="left">Acute disseminated encephalomyelitis</td><td align="left">2</td></tr><tr><td></td><td align="left">Multiple sclerosis</td><td align="left">10</td></tr><tr><td></td><td align="left">Neuromyelitis optica</td><td align="left">1</td></tr><tr><td align="left" colspan="2">Pernicious anaemia</td><td align="left">4</td></tr><tr><td align="left" colspan="2">Systemic lupus erythematosus and related</td><td align="left">53</td></tr><tr><td></td><td align="left">Antiphospholipid syndrome</td><td align="left">2</td></tr><tr><td></td><td align="left">Systemic lupus erythematosus</td><td align="left">51</td></tr><tr><td align="left" colspan="2">Other</td><td align="left">4</td></tr><tr><td></td><td align="left">Addison's disease</td><td align="left">1</td></tr><tr><td></td><td align="left">Crohn's disease</td><td align="left">1</td></tr><tr><td></td><td align="left">MOG antibody-associated diseases</td><td align="left">1</td></tr><tr><td></td><td align="left">PANDAS</td><td align="left">1</td></tr><tr><td align="left" colspan="2">Total</td><td align="left">346</td></tr></tbody></table><table-wrap-foot><fn><p>GABA=γ-aminobutyric-acid. NMDAR=N-methyl-D-aspartate receptor. MOG=myelin oligodendrocyte protein. PANDAS=paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.</p></fn></table-wrap-foot></table-wrap></p>
</sec>
<sec id="cesec20">
<title>Innate immune system</title>
<sec id="cesec30">
<title>Catatonia due to infection</title>
<p id="para260">A systematic review reported that 20% of catatonia has a general medical cause, of which CNS inflammation (comprising both infective and immune causes) accounts for 29%.<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref> Numerous infectious diseases have been reported to cause catatonia. Here, we present the results of a new systematic search of the literature (<xref ref-type="table" rid="tbl1">table 1</xref>; <xref ref-type="sec" rid="sec1">appendix</xref>). We identified 124 cases, the majority of which were published as case reports, with the remaining reported as case series. Laboratory evidence of infection (such as isolation of the organism in the serum, or viral DNA in the cerebrospinal fluid [CSF]) was reported in 85 of the cases (69%). A robust temporal association between the infection and catatonia was reported in 82 of the cases (66%). A previous psychiatric disorder was recorded in 16 cases (13%) and a previous medical disorder in 26 cases (21%), although the absence of a pre-existing condition was often not stated. Only 66 of the cases (53%) recorded the presence of at least two features from the Bush-Francis Catatonia Screening Instrument (BFCSI); the remainder had insufficient description or only one feature.<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref> In some cases, the catatonia resolved with antimicrobial therapy,<xref ref-type="bibr" rid="bib11"><sup>11</sup></xref> but in others, it required treatment with benzodiazepines<xref ref-type="bibr" rid="bib12"><sup>12</sup></xref> or ECT.<xref ref-type="bibr" rid="bib13"><sup>13</sup></xref>
</p>
<p id="para270">How infection might result in catatonia is unclear from the literature. Possibilities include a direct neurotoxic effect, a psychological reaction to the infection, or mediation by an acute-phase response. Out of the 47 cases where a specific virus was implicated, 45 of these involved known neurotropic viruses, suggesting a direct neurotoxic effect. Some bacterial agents, such as <italic>Borrelia burgdorferi</italic> and <italic>Treponema pallidum</italic> are also known to infect the CNS.</p>
<p id="para280">The immunological response might also be important, given that in some neurological disorders, such as meningoencephalitis, damage is caused primarily by an immune reaction.<xref ref-type="bibr" rid="bib14"><sup>14</sup></xref> In several cases, an explicit immune response was suggested by the authors to explain the catatonia, such as in paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS),<xref ref-type="bibr" rid="bib15"><sup>15</sup></xref> or in N-methyl-D-aspartate receptor (NMDAR) encephalitis purportedly triggered by yellow fever vaccination,<xref ref-type="bibr" rid="bib16"><sup>16</sup></xref> herpes simplex virus infection,<xref ref-type="bibr" rid="bib17"><sup>17</sup></xref> or Epstein-Barr virus infection.<xref ref-type="bibr" rid="bib18"><sup>18</sup></xref> In cases of pyrexia of unknown origin in which an infective cause was often assumed, a yet uncharacterised disorder might have been responsible.<xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref>
</p>
</sec>
<sec id="cesec40">
<title>Depression and inflammation</title>
<p id="para290">Although cases of overt catatonia in the context of infections are dramatic, the more common neuropsychiatric presentation of infection is a broader phenotype of illness behaviour that resembles depression. This presentation includes reductions in motor activity, oral intake, and social interaction,<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> all of which are seen in catatonia. Psychomotor activity is also slowed in mild experimentally induced infection.<xref ref-type="bibr" rid="bib21"><sup>21</sup></xref> This might be due to impaired spatial memory performance and aberrant activity in parts of the brain involved in interoception. Hence, the brain's response to inflammation, if severe, could result in a complex movement disorder such as catatonia.<xref ref-type="bibr" rid="bib22">22</xref>, <xref ref-type="bibr" rid="bib23">23</xref>
</p>
<p id="para300">In response to an acute stressor, immune cell trafficking occurs, with the movement of leukocytes to, and within, a target organ.<xref ref-type="bibr" rid="bib24"><sup>24</sup></xref> However, in chronic stress, increased monocyte production and microglial activation result in neuroinflammation and are associated with depressive behaviour.<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> Depression is often associated with raised levels of pro-inflammatory cytokines, granulocytes, and monocytes.<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> Regarding subtypes of depression, atypical depression (characterised by mood reactivity, hyperphagia, hypersomnia, and leaden paralysis)<xref ref-type="bibr" rid="bib25"><sup>25</sup></xref> is most associated with raised inflammatory markers.<xref ref-type="bibr" rid="bib26"><sup>26</sup></xref> Conversely, psychomotor retardation is more commonly seen in melancholic depression, which is less associated with a peripheral pro-inflammatory state.<xref ref-type="bibr" rid="bib26"><sup>26</sup></xref> Seasonal affective disorder has also been associated with a pro-inflammatory state, but there has been little research to date on the motor phenotype of this disorder.<xref ref-type="bibr" rid="bib27"><sup>27</sup></xref>
</p>
</sec>
<sec id="cesec50">
<title>Neuroleptic malignant syndrome and inflammation</title>
<p id="para310">Neuroleptic malignant syndrome is a neurological emergency precipitated by antipsychotic use and characterised by muscular rigidity, autonomic dysfunction, and altered consciousness. Patients treated with antipsychotics who have pre-existing catatonia are at an increased risk of developing neuroleptic malignant syndrome compared with those who do not have catatonia (3·6% <italic>vs</italic> 0·07–1·8%).<xref ref-type="bibr" rid="bib28"><sup>28</sup></xref> Given that no clinical features exist that can reliably distinguish neuroleptic malignant syndrome from malignant catatonia,<xref ref-type="bibr" rid="bib29"><sup>29</sup></xref> some authors consider neuroleptic malignant syndrome to be a specific form of antipsychotic-induced malignant catatonia.<xref ref-type="bibr" rid="bib30"><sup>30</sup></xref> Residual catatonia frequently remains after the resolution of the full syndrome of neuroleptic malignant syndrome.<xref ref-type="bibr" rid="bib31"><sup>31</sup></xref>
</p>
<p id="para320">Some suggest that inflammation is important to the pathophysiology of neuroleptic malignant syndrome, with acute-phase responses such as leukocytosis, thrombocytosis, and low serum iron frequently reported.<xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib33">33</xref> Low serum iron has emerged as a promising biomarker.<xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib33">33</xref> It has been hypothesised that in neuroleptic malignant syndrome, pro-inflammatory cytokines might reduce the levels of the neuroprotective kynurenic acid, impairing the activity of dopaminergic neurons in the midbrain, causing exquisite sensitivity to a further antipsychotic-induced reduction in dopaminergic signalling.<xref ref-type="bibr" rid="bib34"><sup>34</sup></xref> However, an inflammatory profile in the blood might be the consequence of rhabdomyolysis, rather than the primary pathology.</p>
<p id="para330">Serotonin syndrome, a rare adverse effect of antidepressant medication, has also been described as a form of drug-induced catatonia,<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref> but to the authors' knowledge no research has been published linking it to the immune system.<xref ref-type="bibr" rid="bib35"><sup>35</sup></xref>
</p>
</sec>
<sec id="cesec60">
<title>Direct evidence for the acute-phase response</title>
<p id="para340">The acute-phase response is a core part of the innate immune system. The response is initiated by the activation of monocytes and macrophages by a stimulus, such as muscle breakdown, infection, physical injury, or psychological stress. In response to these stimuli, cells release pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-α), which in turn act on receptors throughout the body to promote fever, anorexia, muscle catabolism, and activation of the hypothalamic-pituitary-adrenal axis. Importantly, these cytokines also alter protein synthesis in the liver, causing increased production of acute-phase proteins such as C-reactive protein (CRP), procalcitonin, ferritin, and fibrinogen.<xref ref-type="bibr" rid="bib36">36</xref>, <xref ref-type="bibr" rid="bib37">37</xref> Some features of malignant catatonia bear notable similarities to the acute-phase response, including fever, motor hypoactivity, and autonomic disturbance. Here, we include a summary of the evidence for the presence of systemic inflammation, as measured by acute-phase reactants and related proteins (<xref ref-type="table" rid="tbl3">table 3</xref>
). Creatine kinase (CK) is not an acute-phase marker, but as it is a marker of muscle breakdown, the enzyme is sometimes raised as a downstream consequence of the acute-phase response. The evidence for CK elevation in catatonia is equivocal and could be argued to be the result of muscular rigidity and excessive immobilisation rather than indicating a primary muscular pathology. In one study, a raised CK predicted a good response to treatment with lorazepam.<xref ref-type="bibr" rid="bib45"><sup>45</sup></xref>
<table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Systematic review of inflammatory markers in catatonia</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th align="left"><bold>Study</bold></th><th align="left"><bold>Participants with catatonia</bold></th><th align="left"><bold>Controls</bold></th><th align="left"><bold>Results</bold></th></tr></thead><tbody><tr><td align="left">White blood cell count</td><td align="left">Haouzir et al (2009)<xref ref-type="bibr" rid="bib38"><sup>38</sup></xref></td><td align="left">25 patients with acute catatonia</td><td align="left">50 patients without catatonia with similar diagnoses to patients with catatonia</td><td align="left">No difference in white blood cell count</td></tr><tr><td align="left">White blood cell count</td><td align="left">Rao et al (2011)<xref ref-type="bibr" rid="bib39"><sup>39</sup></xref></td><td align="left">77 patients with catatonia</td><td align="left">None</td><td align="left">Responders to lorazepam had a statistically significantly lower monocyte count than non-responders; no difference in other cell counts</td></tr><tr><td align="left">hsCRP</td><td align="left">Akanji et al (2009)<xref ref-type="bibr" rid="bib40"><sup>40</sup></xref></td><td align="left">12 patients with schizophrenia with prominent catatonic features</td><td align="left">87 patients with schizophrenia without catatonia</td><td align="left">hsCRP concentration statistically significantly higher in patients with catatonia</td></tr><tr><td align="left">Iron</td><td align="left">Haouzir et al (2009)<xref ref-type="bibr" rid="bib38"><sup>38</sup></xref></td><td align="left">25 patients with acute catatonia</td><td align="left">50 patients without catatonia with similar diagnoses to patients with catatonia</td><td align="left">Iron concentration did not differ between patients with and without catatonia</td></tr><tr><td align="left">Iron</td><td align="left">Lee (1998)<xref ref-type="bibr" rid="bib41"><sup>41</sup></xref></td><td align="left">39 patients with catatonia in psychiatric intensive care units</td><td align="left">None</td><td align="left">17 patients had iron concentration below reference range</td></tr><tr><td align="left">Iron</td><td align="left">Peralta et al (1999)<xref ref-type="bibr" rid="bib42"><sup>42</sup></xref></td><td align="left">40 patients with catatonia and psychosis</td><td align="left">40 patients with psychosis without catatonia</td><td align="left">Iron concentration statistically significantly lower in patients without catatonia</td></tr><tr><td align="left">Iron</td><td align="left">Carroll and Goforth (1995)<xref ref-type="bibr" rid="bib43"><sup>43</sup></xref></td><td align="left">12 episodes of catatonia in 11 psychiatric inpatients</td><td align="left">None</td><td align="left">3 patients had iron concentration below reference range</td></tr><tr><td align="left">Iron</td><td align="left">Lakshmana et al (2009)<xref ref-type="bibr" rid="bib44"><sup>44</sup></xref></td><td align="left">40 catatonic patients</td><td align="left">Age-matched and sex-matched psychiatric patients</td><td align="left">No difference in iron concentration between patients with and without catatonia</td></tr><tr><td align="left">CK</td><td align="left">Northoff et al (1996)<xref ref-type="bibr" rid="bib45"><sup>45</sup></xref></td><td align="left">32 hospital inpatients with catatonia</td><td align="left">32 dyskinetic psychiatric patients without catatonia, 32 non-dyskinetic psychiatric patients without catatonia, 32 healthy controls</td><td align="left">CK concentration statistically significantly higher in individuals with catatonia than in healthy controls and non-dyskinetic patients without catatonia; no difference between patients with catatonia and dyskinetic patients without catatonia</td></tr><tr><td align="left">CK</td><td align="left">Haouzir et al (2009)<xref ref-type="bibr" rid="bib38"><sup>38</sup></xref></td><td align="left">25 patients with acute catatonia</td><td align="left">50 patients without catatonia with similar diagnoses to patients with catatonia</td><td align="left">No difference in CK concentration</td></tr><tr><td align="left">CK</td><td align="left">Meltzer (1968)<xref ref-type="bibr" rid="bib46"><sup>46</sup></xref></td><td align="left">Two patients with catatonia</td><td align="left">14 patients with non-catatonic psychoses</td><td align="left">No difference in CK concentration</td></tr><tr><td align="left">D-dimer</td><td align="left">Haouzir et al (2009)<xref ref-type="bibr" rid="bib38"><sup>38</sup></xref></td><td align="left">25 patients with acute catatonia</td><td align="left">50 patients without catatonia with similar diagnoses to patients with catatonia</td><td align="left">D-dimer concentration statistically significantly higher in patients with catatonia</td></tr></tbody></table><table-wrap-foot><fn><p>hsCRP=high-sensitivity C-reactive protein. CK=creatine kinase.</p></fn></table-wrap-foot></table-wrap></p>
<p id="para350">One study found the acute-phase marker, and fibrin degradation product, D-dimer to be raised in all 25 catatonic patients tested, with a mean value 3 times higher than in non-catatonic psychiatric patients.<xref ref-type="bibr" rid="bib38"><sup>38</sup></xref> This finding is consistent with the increased risk of venous thromboembolism in catatonia, but has not yet been replicated.</p>
<p id="para360">High-sensitivity CRP concentration was measured in one study and found to be raised in catatonic patients, but the absolute concentration of CRP was not very elevated (1·23 mg/dL).<xref ref-type="bibr" rid="bib40"><sup>40</sup></xref>
</p>
<p id="para370">Low serum iron was originally hypothesised to be present in catatonia given the similarities to neuroleptic malignant syndrome. Low serum iron is an established feature of the acute-phase response and arises because of the upregulated production of ferritin and hepcidin by the liver.<xref ref-type="bibr" rid="bib47"><sup>47</sup></xref> Two uncontrolled studies have shown that between 25% and 44% of catatonic episodes were accompanied by serum iron concentrations below the reference range.<xref ref-type="bibr" rid="bib41">41</xref>, <xref ref-type="bibr" rid="bib43">43</xref> When catatonic patients have been compared with psychiatric controls however, the results have been ambiguous.<xref ref-type="bibr" rid="bib38">38</xref>, <xref ref-type="bibr" rid="bib42">42</xref>, <xref ref-type="bibr" rid="bib44">44</xref> The authors of one of the negative studies that used unmedicated patients speculated that iron might have been reduced in other reports because of the effect of antipsychotic medications.<xref ref-type="bibr" rid="bib44"><sup>44</sup></xref> In several studies, low serum iron in catatonia has been associated with the subsequent development of neuroleptic malignant syndrome.<xref ref-type="bibr" rid="bib41">41</xref>, <xref ref-type="bibr" rid="bib43">43</xref>, <xref ref-type="bibr" rid="bib48">48</xref> This association might exist because iron is a cofactor for dopamine synthesis,<xref ref-type="bibr" rid="bib49"><sup>49</sup></xref> so a combination of low iron impairing dopamine production and antipsychotic medications blocking dopamine receptors could result in the pathological hypodopaminergic signalling characteristic of neuroleptic malignant syndrome.</p>
</sec>
<sec id="cesec70">
<title>Glial dysfunction</title>
<p id="para380">Abnormalities of cerebral white matter, which is composed of glial cells, have been associated with schizophrenia, depression, and autism.<xref ref-type="bibr" rid="bib50"><sup>50</sup></xref> 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) is a myelin protein that is specific to oligodendrocytes.<xref ref-type="bibr" rid="bib50"><sup>50</sup></xref> In a mouse model, heterozygotes for a <italic>CNP</italic> loss-of-function genotype showed axonal degeneration and low-grade inflammation, along with a depressive and catatonic phenotype.<xref ref-type="bibr" rid="bib51"><sup>51</sup></xref> Furthermore, this behaviour was alleviated by ablation of microglia, suggesting that microglia-mediated neuroinflammation was underlying the phenotype. When this polymorphism was examined in individuals with schizophrenia, a striking association existed with catatonic-depressive behaviour, a finding that was replicated in an independent cohort.<xref ref-type="bibr" rid="bib52"><sup>52</sup></xref> Mutations of mouse genes encoding two other myelin proteins (myelin basic protein [MBP] and myelin proteolipid protein [PLP]) also result in a catatonic phenotype.<xref ref-type="bibr" rid="bib52"><sup>52</sup></xref> How glial dysfunction—because of relevant polymorphisms or other factors—might contribute to the psychomotor features of catatonia clearly represents an important focus of future research.</p>
</sec>
<sec id="cesec80">
<title>Implications of treatment</title>
<p id="para390">The mainstay of current treatment for catatonia is benzodiazepines and ECT, neither of which is classically understood as an immunomodulatory therapy. Benzodiazepines are positive allosteric modulators at the γ-aminobutyric-acid (GABA)-A receptor. Although research into the function of GABA in the immune system is at an early stage, evidence suggests that GABAergic signalling has a role in suppression of immune responses.<xref ref-type="bibr" rid="bib53"><sup>53</sup></xref> Lymphocytes express GABA-A receptors, and activation of these receptors reduces production of pro-inflammatory cytokines.<xref ref-type="bibr" rid="bib53"><sup>53</sup></xref> However, one study specifically on catatonia found higher monocyte counts predicted benzodiazepine non-response.<xref ref-type="bibr" rid="bib39"><sup>39</sup></xref> Data distinguishing different benzodiazepines are sparse, but some benzodiazepines, such as diazepam and lorazepam (both recognised treatments for catatonia) but not clonazepam, also bind to translocator protein (TSPO), a mitochondrial protein associated with phagocyte activity, immune cell migration, and cytokine function.<xref ref-type="bibr" rid="bib54">54</xref>, <xref ref-type="bibr" rid="bib55">55</xref> In rats, diazepam reduces TSPO in the brain and decreases the number of CNS inflammatory cells, giving it a protective function against experimental autoimmune encephalomyelitis.<xref ref-type="bibr" rid="bib55"><sup>55</sup></xref> Reports on other GABA-A receptor modulators are scarce, but epidemiological studies exist that indicate that zolpidem use is associated with higher rates of infections (including of pyelonephritis, which would be unlikely to be related to respiratory depression), suggesting the drug might also have an immunosuppressant role.<xref ref-type="bibr" rid="bib56">56</xref>, <xref ref-type="bibr" rid="bib57">57</xref>
</p>
<p id="para400">Regarding ECT, a single session appears to activate the immune system, increasing concentrations of the cytokines IL-1β, IL-6, IL-10, and TNF-α. However, a course of several sessions appears to down-regulate immune system activity, at least in animal studies.<xref ref-type="bibr" rid="bib58"><sup>58</sup></xref>
</p>
<p id="para410">Minocycline is an antimicrobial drug that also has anti-inflammatory properties.<xref ref-type="bibr" rid="bib59"><sup>59</sup></xref> The drug has been shown to prevent stress-induced microglial changes in rodents<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> and has been proposed as an adjunctive treatment for schizophrenia.<xref ref-type="bibr" rid="bib60"><sup>60</sup></xref> Some evidence suggests that minocycline might reduce negative symptoms in schizophrenia,<xref ref-type="bibr" rid="bib61"><sup>61</sup></xref> some of which (such as poverty of speech, affective blunting, and avolition) overlap with catatonia. However, a 2018 double-blinded, randomised study which specifically aimed to examine the effect of this drug on negative symptoms did not find any benefit.<xref ref-type="bibr" rid="bib62"><sup>62</sup></xref> No studies of which we are aware have investigated minocycline specifically for catatonia, but reports exist of two patients with schizophrenia and prominent catatonic features who responded well to minocycline in the absence of infection.<xref ref-type="bibr" rid="bib63">63</xref>, <xref ref-type="bibr" rid="bib64">64</xref>
</p>
</sec>
<sec id="cesec90">
<title>The evidence for innate immunity</title>
<p id="para420">We have argued that psychological stress and infection both cause a release of pro-inflammatory cytokines, which result in a state of motor hypoactivity. In a normal psychomotor response, this event might be adaptive, allowing conservation of energy for eliminating a pathogen or avoiding a stressor, and resolving when the stressor ends. However, in depression, a prolonged pro-inflammatory state might be maladaptive and cause further dysfunction. Immobilisation itself can also result in activation of the innate immune system.<xref ref-type="bibr" rid="bib65"><sup>65</sup></xref>
</p>
<p id="para430">Studies specifically in catatonia have been sparse and conflicting. An argument could be made that catatonia is an exaggerated version of inflammatory depression, in which extreme psychomotor retardation culminates in stupor and mutism—neurovegetative features of catatonia hypothesised to be due to disordered top-down corticosubcortical signalling.<xref ref-type="bibr" rid="bib66"><sup>66</sup></xref> However, this hypothesis would not explain the perseverative-compulsive behaviours exhibited in catatonia (posturing, stereotypy, mannerism, echophenomena, and perseveration), which have been proposed to arise due to disrupted corticocortical signalling. The infective causes of catatonia are largely pathogens that infect the CNS (<xref ref-type="table" rid="tbl1">table 1</xref>), which suggests that the causality is mediated by neurotoxic mechanisms, rather than by a systemic inflammatory response—although a maladaptive immune response to the pathogen might contribute.</p>
</sec>
</sec>
<sec id="cesec100">
<title>Autoimmunity</title>
<sec id="cesec110">
<title>Autoimmune neurological disorders resembling catatonia</title>
<p id="para440">A plethora of autoimmune neurological diseases exist, many of which, such as multiple sclerosis, neuromyotonia, and Sydenham's chorea, feature prominent movement disorders. We have chosen the examples of stiff person syndrome and narcolepsy to show some particular points of similarity to catatonia.</p>
<p id="para450">Stiff person syndrome is a rare neurological disorder characterised by gradually progressive increased muscle tone with the preservation of muscle power, sensation, and cognitive function. Most patients have autoantibodies against the enzyme glutamic acid decarboxylase (GAD2).<xref ref-type="bibr" rid="bib67"><sup>67</sup></xref> GAD2 is an enzyme that converts glutamate to GABA, although the pathogenicity of GAD2 autoantibodies in stiff person syndrome is not fully established. Given that the disorder bears several similarities to catatonia, one author has suggested testing for GAD2 autoantibodies to distinguish between the two disorders.<xref ref-type="bibr" rid="bib28"><sup>28</sup></xref> The syndromes share immobility, an emotionless facial expression, and marked anxiety. Moreover, hypertonic episodes in stiff person syndrome can have psychological triggers.<xref ref-type="bibr" rid="bib67"><sup>67</sup></xref> As with catatonia, the mainstay of treatment for stiff person syndrome is benzodiazepines; however, immunotherapy in the form of intravenous immunoglobulin, corticosteroids and the anti-B-cell monoclonal antibody rituximab are increasingly used. A stiff person syndrome variant, progressive encephalomyelitis with rigidity and myoclonus, responds dramatically to immunosuppression.<xref ref-type="bibr" rid="bib67">67</xref>, <xref ref-type="bibr" rid="bib68">68</xref>
</p>
<p id="para460">Narcolepsy type 1 is a sleep disorder that arises due to depletion of the orexin-producing neurons in the hypothalamus. Evidence that this event is immune-mediated comes from linkage to <italic>HLA-DQB1*06:02</italic> and outbreaks coinciding with epidemics of, and vaccination to, the H1N1 influenza virus, suggesting a possible role for molecular mimicry.<xref ref-type="bibr" rid="bib69"><sup>69</sup></xref> A small study published in 2012 suggested that some patients with narcolepsy have autoantibodies to the NMDAR, without the seizures or autonomic disturbance characteristic of NMDAR autoimmune encephalitis.<xref ref-type="bibr" rid="bib70"><sup>70</sup></xref> Narcolepsy type 1 also features cataplexy, a sudden loss of motor tone usually triggered by positive emotions. Cataplexy usually lasts for up to 2 min, but occasionally status cataplecticus lasting for hours to days can occur.<xref ref-type="bibr" rid="bib71"><sup>71</sup></xref> This occurrence has been hypothesised to be due to either a prolonged emotional response to the original stimulus, or an emotional response to the cataplexy per se. Here, we show a comparison between cataplexy and catatonia (<xref ref-type="table" rid="tbl4">table 4</xref>
).<table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p>Comparison of catatonia and cataplexy in the context of narcolepsy</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th align="left"><bold>Catatonia</bold></th><th align="left"><bold>Cataplexy</bold></th></tr></thead><tbody><tr><td align="left">Trigger</td><td align="left">Strong negative emotions</td><td align="left">Strong positive emotions</td></tr><tr><td align="left">Tone</td><td align="left">Increased with posturing, but preservation of respiratory muscles</td><td align="left">Atonic with preservation of respiratory muscles</td></tr><tr><td align="left">Awareness</td><td align="left">Retained</td><td align="left">Retained</td></tr><tr><td align="left">Main associated psychiatric disorders</td><td align="left">Depression, psychosis</td><td align="left">Depression, social anxiety</td></tr><tr><td align="left">Pharmacological treatment</td><td align="left">GABA-A receptor agonists</td><td align="left">Antidepressants, sodium oxybate (a GABA-B receptor agonist)</td></tr><tr><td align="left">Duration</td><td align="left">Days to weeks</td><td align="left">Up to 2 min (longer in status cataplecticus)</td></tr></tbody></table><table-wrap-foot><fn><p>GABA=γ-aminobutyric-acid.</p></fn></table-wrap-foot></table-wrap></p>
</sec>
<sec id="cesec120">
<title>Autoimmune disorders causing catatonia</title>
<p id="para470">We did a systematic literature search for autoimmune disorders causing catatonia (<xref ref-type="table" rid="tbl2">table 2</xref>; <xref ref-type="sec" rid="sec1">appendix</xref>). Most are presented in case reports and case series, with some larger case series for NMDAR encephalitis (<xref ref-type="table" rid="tbl5">table 5</xref>
). 224 of the 346 cases (65%) recorded at least two features from the BFCSI.<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref> 18 patients (5%) had previously had a psychiatric disorder and 33 (10%) had previously had a medical disorder, although an absence of a pre-existing condition was often not stated. In some cases, the autoimmune disorder appeared to be the proximal cause of the catatonia. In other cases, the autoimmune disorder was a more distal cause, as in one patient with autoimmune polyendocrine syndrome who developed autoimmune destruction of the adrenal gland (Addison's disease), resulting in hyponatraemia and subsequent extrapontine myelinosis, the latter precipitating catatonia.<xref ref-type="bibr" rid="bib78"><sup>78</sup></xref>
<table-wrap id="tbl5" position="float"><label>Table 5</label><caption><p>Prevalence of catatonia (as identified by authors) in case series of NMDAR encephalitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th align="left"><bold>Participants (N)</bold></th><th align="left"><bold>Cases of catatonia (n [%])</bold></th></tr></thead><tbody><tr><td align="left">Dalmau et al (2008)<xref ref-type="bibr" rid="bib72"><sup>72</sup></xref></td><td align="left">100</td><td align="left">88 (88%)</td></tr><tr><td align="left">Tsutsui et al (2012)<xref ref-type="bibr" rid="bib70"><sup>70</sup></xref></td><td align="left">3</td><td align="left">2 (67%)</td></tr><tr><td align="left">DeSena et al (2014)<xref ref-type="bibr" rid="bib73"><sup>73</sup></xref><xref ref-type="table-fn" rid="tbl5fn1">*</xref></td><td align="left">8</td><td align="left">5 (63%)</td></tr><tr><td align="left">Kruse et al (2015)<xref ref-type="bibr" rid="bib74"><sup>74</sup></xref></td><td align="left">12</td><td align="left">9 (75%)</td></tr><tr><td align="left">Duan et al (2016)<xref ref-type="bibr" rid="bib75"><sup>75</sup></xref></td><td align="left">28</td><td align="left">19 (68%)</td></tr><tr><td align="left">Granata et al (2018)<xref ref-type="bibr" rid="bib76"><sup>76</sup></xref><xref ref-type="table-fn" rid="tbl5fn1">*</xref></td><td align="left">18</td><td align="left">8 (44%)</td></tr><tr><td align="left">Herken and Prüss (2017)<xref ref-type="bibr" rid="bib77"><sup>77</sup></xref><xref ref-type="table-fn" rid="tbl5fn2">†</xref></td><td align="left">53</td><td align="left">10 (19%)</td></tr><tr><td align="left">Total</td><td align="left">222</td><td align="left">141 (64%)</td></tr></tbody></table><table-wrap-foot><fn><p>NMDAR=N-methyl-D-aspartate receptor.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fn1"><label>*</label><p id="cenpara10">All paediatric cases.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fn2"><label>†</label><p id="cenpara20">Relied on retrospective analysis of charts, so probably underestimated prevalence of catatonia.</p></fn></table-wrap-foot></table-wrap></p>
<p id="para480">In addition, 22q11.2 deletion syndrome, which features thymic aplasia and a resultant absence of peripheral T cells,<xref ref-type="bibr" rid="bib79"><sup>79</sup></xref> has also been linked to catatonia.<xref ref-type="bibr" rid="bib80"><sup>80</sup></xref> Whether this association is due to immunodeficiency, the high rates of various autoimmune disorders present in the syndrome, or to another cause remains unclear.</p>
<p id="para490">The most noteworthy result from our systematic review is that 72% (249/346) of all cases of autoimmune catatonia reported were due to NMDAR encephalitis, despite the disorder only being described in 2007 (<xref ref-type="table" rid="tbl2">table 2</xref>).<xref ref-type="bibr" rid="bib81"><sup>81</sup></xref> Before discussing this finding of autoimmunity directed against the CNS in depth, we will illustrate the complexity of autoimmune catatonia with three examples of peripheral autoimmunity.</p>
<p id="para500">Two cases of catatonia in pernicious anaemia have been reported, both of whom responded to vitamin B12 supplementation.<xref ref-type="bibr" rid="bib82">82</xref>, <xref ref-type="bibr" rid="bib83">83</xref> Dietary vitamin B12 deficiency might also cause catatonia.<xref ref-type="bibr" rid="bib84">84</xref>, <xref ref-type="bibr" rid="bib85">85</xref>
</p>
<p id="para510">In thyroid disease, catatonia has been reported in patients with thyroid autoantibodies with hyperthyroid,<xref ref-type="bibr" rid="bib86">86</xref>, <xref ref-type="bibr" rid="bib87">87</xref>, <xref ref-type="bibr" rid="bib88">88</xref> hypothyroid,<xref ref-type="bibr" rid="bib90">90</xref>, <xref ref-type="bibr" rid="bib91">91</xref> and euthyroid<xref ref-type="bibr" rid="bib91">91</xref>, <xref ref-type="bibr" rid="bib92">92</xref> states. However, catatonia has also occurred in hypothyroidism due to thyroidectomy;<xref ref-type="bibr" rid="bib93"><sup>93</sup></xref> whether thyroid status or the presence of the autoantibodies is the causally relevant factor therefore remains unclear.</p>
<p id="para520">In systematic lupus erythematosus, 51 cases of catatonia have been reported, generally with high titres of antinuclear antibody and anti-double-stranded DNA; however, making further comparisons is difficult because testing panels have varied across studies (<xref ref-type="sec" rid="sec1">appendix</xref>).</p>
<p id="para530">One group reported 84 cases of paediatric catatonia of which they suspected 7 had an autoimmune origin, including two patients with evidence of inflammation who were responsive to immunosuppression but who could not be diagnosed with any known disorder.<xref ref-type="bibr" rid="bib94"><sup>94</sup></xref>
</p>
</sec>
<sec id="cesec130">
<title>Autoimmune disorders directed at CNS targets causing catatonia</title>
<p id="para540">PANDAS and the broader concept of paediatric acute-onset neuropsychiatric syndrome (PANS) are characterised by an abrupt onset of obsessive behaviours or motor tics.<xref ref-type="bibr" rid="bib27"><sup>27</sup></xref> This behaviour might be due to molecular mimicry, whereby antigens on the infective agent bear a similarity to and provoke a host immune response to self-CNS antigens.<xref ref-type="bibr" rid="bib95"><sup>95</sup></xref> Antistreptococcal antibodies are often positive,<xref ref-type="bibr" rid="bib96"><sup>96</sup></xref> although results of immunotherapy have been equivocal.<xref ref-type="bibr" rid="bib97"><sup>97</sup></xref> One case has been reported of a boy who developed catatonic symptoms in addition to obsessionality following infection with group A <italic>Streptococcus</italic>; he responded well to lorazepam and plasmapheresis.<xref ref-type="bibr" rid="bib98"><sup>98</sup></xref>
</p>
<p id="para550">Autoimmune encephalopathies, as examples of autoimmune disorders directed at CNS targets, merit special consideration. T-cell mediated disorders, such as acute demyelinating encephalomyelitis can occasionally present with catatonia.<xref ref-type="bibr" rid="bib99"><sup>99</sup></xref> However, catatonia is more commonly a feature of autoimmune encephalitides associated with antineuronal antibodies. These antibodies can cause internalisation of the antigen, inhibiting its function.<xref ref-type="bibr" rid="bib14"><sup>14</sup></xref>
</p>
<p id="para560">That catatonia has been reported in two patients with GABA-A receptor antibodies is unsurprising, given the centrality of benzodiazepines in treatment for catatonia.<xref ref-type="bibr" rid="bib100">100</xref>, <xref ref-type="bibr" rid="bib101">101</xref> Catatonia might be more common than these case reports would suggest, as careful psychiatric phenotyping has not been done among this population.<xref ref-type="bibr" rid="bib102"><sup>102</sup></xref> In one of the patients reported with catatonia, GABA-A receptor antibodies were present in the serum on the original presentation, but not in the context of relapse, highlighting that testing serum only on a single occasion might increase the risk of missing a clinically significant syndrome.<xref ref-type="bibr" rid="bib100"><sup>100</sup></xref>
</p>
<p id="para570">NMDAR encephalitis is increasingly considered as an organic cause of psychosis, although controversy exists as to whether this idea is only relevant in the context of the classical encephalitis or also in isolated psychiatric presentations.<xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib103">103</xref> The association NMDAR encephalitis with catatonia seems to be even stronger than the association with psychosis.<xref ref-type="bibr" rid="bib72"><sup>72</sup></xref> Where catatonia is reported, it is often malignant catatonia and tends to co-occur with psychosis<xref ref-type="bibr" rid="bib104"><sup>104</sup></xref> and mania.<xref ref-type="bibr" rid="bib105"><sup>105</sup></xref> NMDAR encephalitis is strongly linked to neuroleptic malignant syndrome, with one study suggesting as many as 21 out of 36 (58%) patients with NMDAR antibody encephalitis who were administered antipsychotics developed suspected neuroleptic malignant syndrome.<xref ref-type="bibr" rid="bib106"><sup>106</sup></xref> Of the total 222 cases of NMDAR encephalitis documented across seven studies where rates of catatonia were reported, 141 (64%) cases of catatonia were identified (<xref ref-type="table" rid="tbl5">table 5</xref>). The range of catatonic features reported is wide and includes echolalia, grimacing, posturing, and alternating hypermotor and hypomotor activity.<xref ref-type="bibr" rid="bib72"><sup>72</sup></xref>
</p>
<p id="para580">A few studies have examined comparative rates of NMDAR autoantibody positivity among different diagnostic groups. Of 459 patients with psychiatric disorders, two had IgG antibodies against the NMDAR subunit NR1a in serum and CSF; both had catatonia and were ultimately reclassified as having NMDAR encephalitis.<xref ref-type="bibr" rid="bib107"><sup>107</sup></xref> Among 49 inpatients with psychiatric disorders and serum antineuronal antibodies, nine of the 13 patients with NMDAR antibodies had catatonia, compared with only three of the remaining patients.<xref ref-type="bibr" rid="bib74"><sup>74</sup></xref> Another study found higher NMDAR positivity among patients with catatonia than in a control group of healthy volunteers (although controls were younger than the patients and the investigators used an unusual continuous measure of NMDAR immunofluorescence).<xref ref-type="bibr" rid="bib108"><sup>108</sup></xref> One study examined Bush-Francis Catatonia Rating Scale scores in patients with first-episode psychosis and found that catatonic features were actually less common in patients with antineuronal antibodies.<xref ref-type="bibr" rid="bib109"><sup>109</sup></xref> A study published in 2018 by our group with individuals at ultra-high risk of psychosis suggests more severe catatonic features in individuals with NMDAR antibodies.<xref ref-type="bibr" rid="bib110"><sup>110</sup></xref>
</p>
<p id="para590">NMDAR encephalitis has only been described in the last decade but has led to a re-evaluation of encephalitis lethargica,<xref ref-type="bibr" rid="bib111"><sup>111</sup></xref> first recognised in 1917, due to notable similarities.<xref ref-type="bibr" rid="bib112"><sup>112</sup></xref> Encephalitis lethargica is characterised by profound sleep impairment (insomnia, hypersomnia, or sleep inversion), extrapyramidal movement deficits, and neuropsychiatric symptoms.<xref ref-type="bibr" rid="bib113"><sup>113</sup></xref> Although historically linked to the 1918 influenza pandemic, the evidence for a causal association is sparse.<xref ref-type="bibr" rid="bib113"><sup>113</sup></xref> More recently, investigations have found a high prevalence of antibodies to the NMDAR and the dopamine D2 receptor in the serum of children with encephalitis lethargica, raising the intriguing prospect that many patients exhibiting catatonia previously diagnosed with the disorder, might have instead had antibody-mediated encephalitis.<xref ref-type="bibr" rid="bib114"><sup>114</sup></xref>
</p>
</sec>
<sec id="cesec140">
<title>A model for autoimmunity in catatonia</title>
<p id="para600">When we considered the role of the innate immune system, we considered the possibility that inflammation itself was responsible for the stuporous aspects of catatonia. As far as adaptive immunity is concerned, the specificity of the antigen might be the most important determinant of the resulting neuropsychiatric phenotype, including catatonia. The downstream effect of immune activation is dependent on the antigen targeted. Autoimmune neurological disorders present differently depending on the target for autoantibodies or T cells; frequently these targets are neurotransmitter receptors with ensuing downstream effects on receptor dysfunction. In autoimmune encephalitis, the presentation depends on the specific antibodies present.<xref ref-type="bibr" rid="bib115"><sup>115</sup></xref> In the specific case of NMDAR encephalitis, often little evidence exists of complement activation and neuronal degeneration.<xref ref-type="bibr" rid="bib116"><sup>116</sup></xref> The fact that ketamine and phencyclidine—both NMDAR antagonists—cause catatonia<xref ref-type="bibr" rid="bib117"><sup>117</sup></xref> suggests that NMDAR antagonism is responsible, the implication being that NMDAR antibody encephalitis is more usefully understood as a synaptopathy. Genetic hypofunction of the NMDAR due to <italic>GRIN1</italic> mutation also appears to predispose to psychosis.<xref ref-type="bibr" rid="bib118"><sup>118</sup></xref> Similarly, benzodiazepine withdrawal presents similarly to GABA-A receptor encephalitis.<xref ref-type="bibr" rid="bib119">119</xref>, <xref ref-type="bibr" rid="bib120">120</xref>
</p>
<p id="para610">Autoimmunity, therefore, appears to cause catatonia primarily by specific action against central or peripheral antigens; however, secondary inflammation could perpetuate a phenotype-relevant immune response.</p>
</sec>
<sec id="cesec150">
<title>A model for glutamatergic hypofunction in catatonia</title>
<p id="para620">The close association between NMDAR encephalitis and catatonia might provide valuable insight into the pathophysiology of catatonia. NMDAR encephalitis causes internalisation of the NMDAR, resulting in a reversible reduction in the number of receptors and impaired α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated long-term potentiation.<xref ref-type="bibr" rid="bib121">121</xref>, <xref ref-type="bibr" rid="bib122">122</xref> This idea is consistent with catatonia also resulting from use of the recreational non-competitive NMDAR antagonists, ketamine, and phencyclidine.<xref ref-type="bibr" rid="bib117">117</xref>, <xref ref-type="bibr" rid="bib123">123</xref>
</p>
<p id="para630">To integrate findings of effective treatment with GABA-A receptor agonists and NMDAR antagonists, Northoff<xref ref-type="bibr" rid="bib66"><sup>66</sup></xref> has proposed a model of catatonia in which the normal inhibition of excitatory glutamatergic corticocortical association fibres by GABAergic neurons in the orbitofrontal region is impaired. In mice, the NMDAR antagonist dizocilpine (also known as MK-801) shows a bimodal effect on grooming and rearing behaviour: at low doses, this behaviour is suppressed, but as the dose increases, behaviour normalises, before being suppressed again at higher doses.<xref ref-type="bibr" rid="bib124">124</xref>, <xref ref-type="bibr" rid="bib125">125</xref> This effect might explain why catatonia is characterised not only by immobility, but also occasionally by catatonic excitement. An explanation for this finding might rely on the knowledge that the NMDAR is expressed by excitatory glutamatergic neurons and by inhibitory GABAergic neurons.<xref ref-type="bibr" rid="bib126"><sup>126</sup></xref> Moreover, both reduced and excessive NMDAR activity can result in neuronal apoptosis,<xref ref-type="bibr" rid="bib127"><sup>127</sup></xref> but at physiological levels can also promote neuronal survival.<xref ref-type="bibr" rid="bib128"><sup>128</sup></xref>
</p>
<p id="para640">Dalmau and colleagues<xref ref-type="bibr" rid="bib111"><sup>111</sup></xref> have proposed a model for antiNMDAR encephalitis, in which increasing NMDAR blockade results initially in behavioural and psychotic symptoms, and at higher antibody titres, neurological and autonomic dysfunction. One hypothesis would be that catatonia occupies the ground between these two states (<xref ref-type="fig" rid="fig1">figure</xref>
).<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref> Pharmacological or antibody-mediated NMDAR hypofunction could both cause catatonia and result in progression to malignant catatonia.<fig id="fig1"><label>Figure</label><caption><p>A model for glutamatergic hypofunction in catatonia</p><p>NMDAR= N-methyl-D-aspartate receptor.</p></caption><graphic xlink:href="gr1_lrg"></graphic></fig></p>
</sec>
</sec>
<sec id="cesec160">
<title>Conclusion</title>
<p id="para650">Catatonia is heterogeneous in presentation and cause. However, the generally favourable response to treatment with benzodiazepines or ECT suggests a common pathophysiology. Activation of the innate immune system can lead to the neurovegetative features of catatonia, but the evidence for the acute phase response in catatonia is preliminary and sometimes conflicting. Moreover, whether any peripheral inflammation in catatonia arises secondary to immobility and muscle breakdown is unknown. Examining the association of catatonia with the adaptive immune system reveals a strong and specific association with NMDAR encephalitis, which can cause the full range of catatonic features. This finding suggests that adaptive immunity can cause catatonia through action at specific extracellular antigens, rather than immune activation per se. Additionally, this illustrates the importance of glutamatergic function in catatonia. As more autoimmune disorders are characterised, more cases of catatonia might be explained in this way.</p>
<p id="para660">Although we have considered the innate and adaptive immune systems separately, in reality, they are deeply interconnected. For instance, NMDAR encephalitis (a disorder of the adaptive immune system) entails a very high risk of neuroleptic malignant syndrome (a disorder with prominent activation of the innate immune system). Malignant catatonia remains an enigmatic entity that could possibly be accounted for by autoimmune disorders such as NMDAR encephalitis.</p>
<p id="para670">Finally, is it possible to conclude whether catatonia is due to activation of the immune system? In many cases, little compelling evidence exists for this. However, where infection or autoimmunity are directed at specific targets in the CNS or periphery, a high risk of catatonia is apparent. Further investigations based on this concept (<xref ref-type="boxed-text" rid="box1">panel</xref>
) might assist in elucidating pathophysiological mechanisms and improving the treatment of catatonia.<boxed-text id="box1"><label>Panel</label><caption><title>Questions for future research</title></caption><p id="para10">
<bold>Epidemiology</bold>
</p><p id="para20">
<list id="celist10" list-type="simple"><list-item id="celistitem10"><label>•</label><p id="para30">Is catatonia overrepresented in individuals with autoimmune disorders?</p></list-item><list-item id="celistitem20"><label>•</label><p id="para40">What are the rates of catatonia in GABA-AR encephalitis when systematic detection methods are used?</p></list-item></list>
</p><p id="para50">
<bold>Laboratory investigations</bold>
</p><p id="para60">
<list id="celist20" list-type="simple"><list-item id="celistitem30"><label>•</label><p id="para70">In studies of depression, is there evidence that raised inflammatory markers are associated with catatonic features?</p></list-item><list-item id="celistitem40"><label>•</label><p id="para80">Do relapsing and remitting inflammatory markers exist in periodic catatonia?</p></list-item><list-item id="celistitem50"><label>•</label><p id="para90">Are patients with catatonia more likely to have antibodies to N-methyl-D-aspartate (NMDA) receptor, γ-aminobutyric-acid (GABA)-A receptor, glutamic acid decarboxylase (GAD2) and other encephalitis-associated antibodies?</p></list-item><list-item id="celistitem60"><label>•</label><p id="para100">Will large genetic studies of catatonia show linkage to HLA or other immune-specific regions?</p></list-item><list-item id="celistitem70"><label>•</label><p id="para110">Do inflammatory markers predictors response to electroconvulsive therapy?</p></list-item></list>
</p><p id="para120">
<bold>Neuroimaging</bold>
</p><p id="para130">
<list id="celist30" list-type="simple"><list-item id="celistitem80"><label>•</label><p id="para140">Does a reduced density of NMDA receptors exist in catatonia in single-photon-emission CT (SPECT) or PET studies?</p></list-item><list-item id="celistitem90"><label>•</label><p id="para150">Will the use of specific ligands reveal CNS immune activation (eg, mediated by microglia or astrocytes) in catatonia?</p></list-item></list>
</p><p id="para160">
<bold>Therapy</bold>
</p><p id="para170">
<list id="celist40" list-type="simple"><list-item id="celistitem100"><label>•</label><p id="para180">Is immunomodulatory therapy (such as with corticosteroids, plasmapheresis, or rituximab) an appropriate treatment option in catatonia?</p></list-item><list-item id="celistitem110"><label>•</label><p id="para190">Is minocycline an effective treatment for catatonia?</p></list-item><list-item id="celistitem120"><label>•</label><p id="para200">Is immunosuppressant therapy effective for neuroleptic malignant syndrome?</p></list-item></list>
</p></boxed-text></p>
</sec>
<sec id="cesec170">
<title>Search strategy and selection criteria</title>
<p id="para680">
<boxed-text id="cetextbox10"><p id="para690">We searched PubMed for articles published up to Sept 31, 2018, with the terms “catatoni*” in association with any of the following terms: “immune*”, “autoimmun*”, “inflame*”, “T-cell”, “B-cell”, “glia*”, “microglia*”, “acute phase”, “innate”, “adaptive”, “encephalitis”, “antibod*”, “infect*”, “interleukin”, “cytokine”, “monocyte”, “macrophage”, “leukocyte”, “lymphocyte”, “granulocyte”, “phagocyte”, “TNF”, “C-reactive protein”, “dendritic cell”, and “immunoglobulin”. This primary search along with the references of selected review articles revealed three areas that were suitable for systematic summaries of the literature: infective causes of catatonia, autoimmune causes of catatonia, and inflammatory markers in catatonia. To investigate these areas, we searched six databases (AMED, BNI, CNINAHL, Embase, MEDLINE, PsycINFO, and PubMed) for catatonia and MESH terms (or equivalent) in conjunction with relevant specific search terms (eg, “infect*”, “virus”, “bacteria”). After deduplication, articles were screened via their titles and abstracts before relevant full-text articles were reviewed by the first author and systematically included in tables in the manuscript. Only articles with full texts or sufficiently detailed abstracts written in English were included.</p></boxed-text>
</p>
</sec>
</body>
<back>
<ref-list id="bibl10">
<title>References</title>
<ref id="bib1">
<label>1</label>
<element-citation id="sbref10" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Fink</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>M</given-names>
</name>
</person-group>
<chapter-title>Catatonia: a clinician's guide to diagnosis and treatment</chapter-title>
<year>2006</year>
<publisher-name>Cambridge University Press</publisher-name>
<publisher-loc>New York, NY</publisher-loc>
</element-citation>
</ref>
<ref id="bib2">
<label>2</label>
<element-citation id="sbref20" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walther</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stegmayer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Heckers</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Structure and neural mechanisms of catatonia</article-title>
<source/>Lancet Psychiatry
          <year>2019</year>
<comment>published online June 10.</comment>
<pub-id pub-id-type="doi">10.1016/S2215-0366(18)30474-7</pub-id>
</element-citation>
</ref>
<ref id="bib3">
<label>3</label>
<element-citation id="sbref30" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clinebell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Azzam</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Gopalan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Haskett</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Guidelines for preventing common medical complications of catatonia: case report and literature review</article-title>
<source/>J Clin Psychiatry
          <volume>75</volume>
<year>2014</year>
<fpage>644</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="pmid">25004188</pub-id>
</element-citation>
</ref>
<ref id="bib4">
<label>4</label>
<element-citation id="sbref40" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nicolson</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>SZ</given-names>
</name>
<name>
<surname>Heckers</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The diagnostic criteria and structure of catatonia</article-title>
<source/>Schizophr Res
          <volume>164</volume>
<year>2015</year>
<fpage>256</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="pmid">25595653</pub-id>
</element-citation>
</ref>
<ref id="bib5">
<label>5</label>
<element-citation id="sbref50" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peralta</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cuesta</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Mata</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>The Kahlbaum syndrome: a study of its clinical validity, nosological status, and relationship with schizophrenia and mood disorder</article-title>
<source/>Compr Psychiatry
          <volume>38</volume>
<year>1997</year>
<fpage>61</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="pmid">8980874</pub-id>
</element-citation>
</ref>
<ref id="bib6">
<label>6</label>
<element-citation id="sbref60" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kirk</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>The syndrome of Karl Ludwig Kahlbaum</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <volume>49</volume>
<year>1986</year>
<fpage>991</fpage>
<lpage>996</lpage>
<pub-id pub-id-type="pmid">3760905</pub-id>
</element-citation>
</ref>
<ref id="bib7">
<label>7</label>
<element-citation id="sbref70" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Diwani</surname>
<given-names>AAJ</given-names>
</name>
<name>
<surname>Pollak</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Irani</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Lennox</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>Psychosis: an autoimmune disease?</article-title>
<source/>Immunology
          <volume>152</volume>
<year>2017</year>
<fpage>388</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="pmid">28704576</pub-id>
</element-citation>
</ref>
<ref id="bib8">
<label>8</label>
<element-citation id="sbref80" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wohleb</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Integrating neuroimmune systems in the neurobiology of depression</article-title>
<source/>Nat Rev Neurosci
          <volume>17</volume>
<year>2016</year>
<fpage>497</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="pmid">27277867</pub-id>
</element-citation>
</ref>
<ref id="bib9">
<label>9</label>
<element-citation id="sbref90" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oldham</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>The probability that catatonia in the hospital has a medical cause and the relative proportions of its causes: a systematic review</article-title>
<source/>Psychosomatics
          <volume>59</volume>
<year>2018</year>
<fpage>333</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="pmid">29776679</pub-id>
</element-citation>
</ref>
<ref id="bib10">
<label>10</label>
<element-citation id="sbref100" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bush</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fink</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Petrides</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dowling</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Catatonia. I. Rating scale and standardized examination</article-title>
<source/>Acta Psychiatr Scand
          <volume>93</volume>
<year>1996</year>
<fpage>129</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="pmid">8686483</pub-id>
</element-citation>
</ref>
<ref id="bib11">
<label>11</label>
<element-citation id="sbref110" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfister</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Preac-Mursic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wilske</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Catatonic syndrome in acute severe encephalitis due to Borrelia burgdorferi infection</article-title>
<source/>Neurology
          <volume>43</volume>
<year>1993</year>
<fpage>433</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="pmid">8437717</pub-id>
</element-citation>
</ref>
<ref id="bib12">
<label>12</label>
<element-citation id="sbref120" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snyder</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Prenzlauer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Catatonia in a patient with AIDS-related dementia</article-title>
<source/>J Clin Psychiatry
          <volume>53</volume>
<year>1992</year>
<fpage>414</fpage>
</element-citation>
</ref>
<ref id="bib13">
<label>13</label>
<element-citation id="sbref130" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sall</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Salamon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Allgulander</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Owe-Larsson</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Psychiatric symptoms and disorders in HIV infected mine workers in South Africa: a retrospective descriptive study of acute first admissions</article-title>
<source/>African J Psychiatry (Johannesbg)
          <volume>12</volume>
<year>2009</year>
<fpage>206</fpage>
<lpage>212</lpage>
</element-citation>
</ref>
<ref id="bib14">
<label>14</label>
<element-citation id="sbref140" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waisman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liblau</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Becher</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Innate and adaptive immune responses in the CNS</article-title>
<source/>Lancet Neurol
          <volume>14</volume>
<year>2015</year>
<fpage>945</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="pmid">26293566</pub-id>
</element-citation>
</ref>
<ref id="bib15">
<label>15</label>
<element-citation id="sbref150" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dell</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <volume>44</volume>
<year>2005</year>
<fpage>1145</fpage>
<lpage>1150</lpage>
<pub-id pub-id-type="pmid">16239863</pub-id>
</element-citation>
</ref>
<ref id="bib16">
<label>16</label>
<element-citation id="sbref160" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hozakova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Slonkova</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blahutova</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Anti-NMDAR encephalitis as a serious adverse event probably related to yellow fever vaccination</article-title>
<source/>Klin Mikrobiol Infekc Lek
          <volume>24</volume>
<year>2018</year>
<fpage>17</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">30016535</pub-id>
</element-citation>
</ref>
<ref id="bib17">
<label>17</label>
<element-citation id="sbref170" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schein</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gagneux-Brunon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Antoine</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Anti-N-methyl-D-aspartate receptor encephalitis after herpes simplex virus-associated encephalitis: an emerging disease with diagnosis and therapeutic challenges</article-title>
<source/>Infection
          <volume>45</volume>
<year>2017</year>
<fpage>545</fpage>
<lpage>549</lpage>
<pub-id pub-id-type="pmid">27826871</pub-id>
</element-citation>
</ref>
<ref id="bib18">
<label>18</label>
<element-citation id="sbref180" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derksen</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>van der Hoeven</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Goraj</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Molenaar</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Severe anti NMDA encephalitis and EBV infection</article-title>
<source/>Neth J Crit Care
          <volume>17</volume>
<year>2013</year>
<fpage>19</fpage>
<lpage>21</lpage>
</element-citation>
</ref>
<ref id="bib19">
<label>19</label>
<element-citation id="sbref190" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Unni</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Shivakumar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dutta</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Chandrasekaran</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Fever of unknown cause presenting as Catatonia</article-title>
<source/>J Assoc Physicians India
          <volume>43</volume>
<year>1995</year>
<fpage>134</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">9282682</pub-id>
</element-citation>
</ref>
<ref id="bib20">
<label>20</label>
<element-citation id="sbref200" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Powers</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Douglass</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Waziri</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Hyperpyrexia in catatonic states</article-title>
<source/>Dis Nerv Syst
          <volume>37</volume>
<year>1976</year>
<fpage>359</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="pmid">1277987</pub-id>
</element-citation>
</ref>
<ref id="bib21">
<label>21</label>
<element-citation id="sbref210" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Tyrrell</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Al-Nakib</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Effects of experimentally induced respiratory virus infections and illness on psychomotor performance</article-title>
<source/>Neuropsychobiology
          <volume>18</volume>
<year>1987</year>
<fpage>144</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="pmid">3453430</pub-id>
</element-citation>
</ref>
<ref id="bib22">
<label>22</label>
<element-citation id="sbref220" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Brydon</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Neural origins of human sickness in interoceptive responses to inflammation</article-title>
<source/>Biol Psychiatry
          <volume>66</volume>
<year>2009</year>
<fpage>415</fpage>
<lpage>422</lpage>
<pub-id pub-id-type="pmid">19409533</pub-id>
</element-citation>
</ref>
<ref id="bib23">
<label>23</label>
<element-citation id="sbref230" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Doeller</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Voon</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Critchley</surname>
<given-names>HD</given-names>
</name>
</person-group>
<article-title>Peripheral inflammation acutely impairs human spatial memory via actions on medial temporal lobe glucose metabolism</article-title>
<source/>Biol Psychiatry
          <volume>76</volume>
<year>2014</year>
<fpage>585</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="pmid">24534013</pub-id>
</element-citation>
</ref>
<ref id="bib24">
<label>24</label>
<element-citation id="sbref240" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Workman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Potential animal models of seasonal affective disorder</article-title>
<source/>Neurosci Biobehav Rev
          <volume>35</volume>
<year>2011</year>
<fpage>669</fpage>
<lpage>679</lpage>
<pub-id pub-id-type="pmid">20800614</pub-id>
</element-citation>
</ref>
<ref id="bib25">
<label>25</label>
<element-citation id="sbref250" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Atypical Depression</article-title>
<source/>Psychiatry (Edgmont)
          <volume>3</volume>
<year>2006</year>
<fpage>33</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">21103169</pub-id>
</element-citation>
</ref>
<ref id="bib26">
<label>26</label>
<element-citation id="sbref260" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penninx</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Milaneschi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lamers</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vogelzangs</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile</article-title>
<source/>BMC Med
          <volume>11</volume>
<year>2013</year>
<fpage>129</fpage>
<pub-id pub-id-type="pmid">23672628</pub-id>
</element-citation>
</ref>
<ref id="bib27">
<label>27</label>
<element-citation id="sbref270" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotype</article-title>
<source/>J Child Adolesc Psychopharmacol
          <volume>25</volume>
<year>2015</year>
<fpage>14</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">25314221</pub-id>
</element-citation>
</ref>
<ref id="bib28">
<label>28</label>
<element-citation id="sbref280" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rasmussen</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mazurek</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Rosebush</surname>
<given-names>PI</given-names>
</name>
</person-group>
<article-title>Catatonia: our current understanding of its diagnosis, treatment and pathophysiology</article-title>
<source/>World J Psychiatry
          <volume>6</volume>
<year>2016</year>
<fpage>391</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="pmid">28078203</pub-id>
</element-citation>
</ref>
<ref id="bib29">
<label>29</label>
<element-citation id="sbref290" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>The nondichotomy between lethal catatonia and neuroleptic malignant syndrome</article-title>
<source/>J Clin Psychopharmacol
          <volume>17</volume>
<year>1997</year>
<fpage>235</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="pmid">9169979</pub-id>
</element-citation>
</ref>
<ref id="bib30">
<label>30</label>
<element-citation id="sbref300" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fink</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Recognizing NMS as a type of catatonia</article-title>
<source/>Neuropsychiatry Neuropsychol Behav Neurol
          <volume>8</volume>
<year>1995</year>
<fpage>75</fpage>
<lpage>76</lpage>
</element-citation>
</ref>
<ref id="bib31">
<label>31</label>
<element-citation id="sbref310" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caroff</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Keck</surname>
<given-names>PE</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Francis</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Residual catatonic state following neuroleptic malignant syndrome</article-title>
<source/>J Clin Psychopharmacol
          <volume>20</volume>
<year>2000</year>
<fpage>257</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="pmid">10770467</pub-id>
</element-citation>
</ref>
<ref id="bib32">
<label>32</label>
<element-citation id="sbref320" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosebush</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A prospective analysis of 24 episodes of neuroleptic malignant syndrome</article-title>
<source/>Am J Psychiatry
          <volume>146</volume>
<year>1989</year>
<fpage>717</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="pmid">2567121</pub-id>
</element-citation>
</ref>
<ref id="bib33">
<label>33</label>
<element-citation id="sbref330" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anglin</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rosebush</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Mazurek</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Neuroleptic malignant syndrome: a neuroimmunologic hypothesis</article-title>
<source/>CMAJ
          <volume>182</volume>
<year>2010</year>
<fpage>E834</fpage>
<lpage>E838</lpage>
<pub-id pub-id-type="pmid">20696799</pub-id>
</element-citation>
</ref>
<ref id="bib34">
<label>34</label>
<element-citation id="sbref340" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oruch</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pryme</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Engelsen</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Lund</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Neuroleptic malignant syndrome: an easily overlooked neurologic emergency</article-title>
<source/>Neuropsychiatr Dis Treat
          <volume>13</volume>
<year>2017</year>
<fpage>161</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="pmid">28144147</pub-id>
</element-citation>
</ref>
<ref id="bib35">
<label>35</label>
<element-citation id="sbref350" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyer</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The serotonin syndrome</article-title>
<source/>N Engl J Med
          <volume>352</volume>
<year>2005</year>
<fpage>1112</fpage>
<lpage>1120</lpage>
<pub-id pub-id-type="pmid">15784664</pub-id>
</element-citation>
</ref>
<ref id="bib36">
<label>36</label>
<element-citation id="sbref360" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Markanday</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Acute phase reactants in infections: evidence-based review and a guide for clinicians</article-title>
<source/>Open Forum Infect Dis
          <volume>2</volume>
<year>2015</year>
<object-id pub-id-type="publisher-id">ofv098
</object-id>
</element-citation>
</ref>
<ref id="bib37">
<label>37</label>
<element-citation id="sbref370" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gruys</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Toussaint</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Niewold</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Koopmans</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Acute phase reaction and acute phase proteins</article-title>
<source/>J Zhejiang Univ Sci B
          <volume>6</volume>
<year>2005</year>
<fpage>1045</fpage>
<lpage>1056</lpage>
<pub-id pub-id-type="pmid">16252337</pub-id>
</element-citation>
</ref>
<ref id="bib38">
<label>38</label>
<element-citation id="sbref380" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haouzir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lemoine</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Desbordes</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The role of coagulation marker fibrin D-dimer in early diagnosis of catatonia</article-title>
<source/>Psychiatry Res
          <volume>168</volume>
<year>2009</year>
<fpage>78</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">19447502</pub-id>
</element-citation>
</ref>
<ref id="bib39">
<label>39</label>
<element-citation id="sbref390" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Mutalik</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Kasal</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Monocyte abnormality in catatonia: revisiting the immune theory of catatonia</article-title>
<source/>J ECT
          <volume>27</volume>
<year>2011</year>
<fpage>e53</fpage>
<lpage>e54</lpage>
<pub-id pub-id-type="pmid">21865953</pub-id>
</element-citation>
</ref>
<ref id="bib40">
<label>40</label>
<element-citation id="sbref400" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akanji</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Ohaeri</surname>
<given-names>JU</given-names>
</name>
<name>
<surname>Al-Shammri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fatania</surname>
<given-names>HR</given-names>
</name>
</person-group>
<article-title>Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients</article-title>
<source/>Psychiatry Res
          <volume>169</volume>
<year>2009</year>
<fpage>56</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">19619902</pub-id>
</element-citation>
</ref>
<ref id="bib41">
<label>41</label>
<element-citation id="sbref410" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Serum iron in catatonia and neuroleptic malignant syndrome</article-title>
<source/>Biol Psychiatry
          <volume>44</volume>
<year>1998</year>
<fpage>499</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="pmid">9777183</pub-id>
</element-citation>
</ref>
<ref id="bib42">
<label>42</label>
<element-citation id="sbref420" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peralta</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cuesta</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Mata</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Perez-Nievas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Natividad</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Serum iron in catatonic and noncatatonic psychotic patients</article-title>
<source/>Biol Psychiatry
          <volume>45</volume>
<year>1999</year>
<fpage>788</fpage>
<lpage>790</lpage>
<pub-id pub-id-type="pmid">10188010</pub-id>
</element-citation>
</ref>
<ref id="bib43">
<label>43</label>
<element-citation id="sbref430" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Goforth</surname>
<given-names>HW</given-names>
</name>
</person-group>
<article-title>Serum iron in catatonia</article-title>
<source/>Biol Psychiatry
          <volume>38</volume>
<year>1995</year>
<fpage>776</fpage>
<lpage>777</lpage>
<pub-id pub-id-type="pmid">8580236</pub-id>
</element-citation>
</ref>
<ref id="bib44">
<label>44</label>
<element-citation id="sbref440" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lakshmana</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Christopher</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Serum iron levels in catatonia</article-title>
<source/>Indian J Psychiatry
          <volume>51</volume>
<year>2009</year>
<fpage>153</fpage>
<pub-id pub-id-type="pmid">19823638</pub-id>
</element-citation>
</ref>
<ref id="bib45">
<label>45</label>
<element-citation id="sbref450" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Northoff</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wenke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pflug</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients</article-title>
<source/>Psychol Med
          <volume>26</volume>
<year>1996</year>
<fpage>547</fpage>
<lpage>553</lpage>
<pub-id pub-id-type="pmid">8733213</pub-id>
</element-citation>
</ref>
<ref id="bib46">
<label>46</label>
<element-citation id="sbref460" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meltzer</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Creatine kinase and aldolase in serum: abnormality common to acute psychoses</article-title>
<source/>Science
          <volume>159</volume>
<year>1968</year>
<fpage>1368</fpage>
<lpage>1370</lpage>
<pub-id pub-id-type="pmid">5644267</pub-id>
</element-citation>
</ref>
<ref id="bib47">
<label>47</label>
<element-citation id="sbref470" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Northrop-Clewes</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Interpreting indicators of iron status during an acute phase response—lessons from malaria and human immunodeficiency virus</article-title>
<source/>Ann Clin Biochem
          <volume>45</volume>
<year>2008</year>
<fpage>18</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">18275670</pub-id>
</element-citation>
</ref>
<ref id="bib48">
<label>48</label>
<element-citation id="sbref480" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raja</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Altavista</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Cavallari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lubich</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Neuroleptic malignant syndrome and catatonia</article-title>
<source/>Eur Arch Psychiatry Clin Neurosci
          <volume>243</volume>
<year>1994</year>
<fpage>299</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="pmid">7913834</pub-id>
</element-citation>
</ref>
<ref id="bib49">
<label>49</label>
<element-citation id="sbref490" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wessling-Resnick</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Iron and mechanisms of emotional behavior</article-title>
<source/>J Nutr Biochem
          <volume>25</volume>
<year>2014</year>
<fpage>1101</fpage>
<lpage>1107</lpage>
<pub-id pub-id-type="pmid">25154570</pub-id>
</element-citation>
</ref>
<ref id="bib50">
<label>50</label>
<element-citation id="sbref500" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pease-Raissi</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Micro(glial)-managing executive function: white matter inflammation drives catatonia</article-title>
<source/>J Clin Invest
          <volume>128</volume>
<year>2017</year>
<fpage>564</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="pmid">29252213</pub-id>
</element-citation>
</ref>
<ref id="bib51">
<label>51</label>
<element-citation id="sbref510" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagemeyer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Goebbels</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Papiol</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A myelin gene causative of a catatonia-depression syndrome upon aging</article-title>
<source/>EMBO Mol Med
          <volume>4</volume>
<year>2012</year>
<fpage>528</fpage>
<lpage>539</lpage>
<pub-id pub-id-type="pmid">22473874</pub-id>
</element-citation>
</ref>
<ref id="bib52">
<label>52</label>
<element-citation id="sbref520" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janova</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arinrad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Balmuth</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Microglia ablation alleviates myelin-associated catatonic signs in mice</article-title>
<source/>J Clin Invest
          <volume>128</volume>
<year>2017</year>
<fpage>734</fpage>
<lpage>745</lpage>
<pub-id pub-id-type="pmid">29252214</pub-id>
</element-citation>
</ref>
<ref id="bib53">
<label>53</label>
<element-citation id="sbref530" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prud'homme</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Glinka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Immunological GABAergic interactions and therapeutic applications in autoimmune diseases</article-title>
<source/>Autoimmun Rev
          <volume>14</volume>
<year>2015</year>
<fpage>1048</fpage>
<lpage>1056</lpage>
<pub-id pub-id-type="pmid">26226414</pub-id>
</element-citation>
</ref>
<ref id="bib54">
<label>54</label>
<element-citation id="sbref540" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramirez</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Niraula</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sheridan</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>GABAergic modulation with classical benzodiazepines prevent stress-induced neuro-immune dysregulation and behavioral alterations</article-title>
<source/>Brain Behav Immun
          <volume>51</volume>
<year>2016</year>
<fpage>154</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="pmid">26342944</pub-id>
</element-citation>
</ref>
<ref id="bib55">
<label>55</label>
<element-citation id="sbref550" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez Hurst</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zanetti</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Baez</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Bibolini</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bouzat</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Diazepam treatment reduces inflammatory cells and mediators in the central nervous system of rats with experimental autoimmune encephalomyelitis</article-title>
<source/>J Neuroimmunol
          <volume>313</volume>
<year>2017</year>
<fpage>145</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="pmid">28992974</pub-id>
</element-citation>
</ref>
<ref id="bib56">
<label>56</label>
<element-citation id="sbref560" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>YS</given-names>
</name>
</person-group>
<article-title>The association between zolpidem and infection in patients with sleep disturbance</article-title>
<source/>J Psychiatr Res
          <volume>54</volume>
<year>2014</year>
<fpage>116</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="pmid">24721551</pub-id>
</element-citation>
</ref>
<ref id="bib57">
<label>57</label>
<element-citation id="sbref570" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Sheu</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>Use of zolpidem and risk of acute pyelonephritis in women: a population-based case-control study in Taiwan</article-title>
<source/>J Clin Pharmacol
          <volume>57</volume>
<year>2017</year>
<fpage>376</fpage>
<lpage>381</lpage>
<pub-id pub-id-type="pmid">27539679</pub-id>
</element-citation>
</ref>
<ref id="bib58">
<label>58</label>
<element-citation id="sbref580" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guloksuz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rutten</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Arts</surname>
<given-names>B</given-names>
</name>
<name>
<surname>van Os</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kenis</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The immune system and electroconvulsive therapy for depression</article-title>
<source/>J ECT
          <volume>30</volume>
<year>2014</year>
<fpage>132</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="pmid">24755720</pub-id>
</element-citation>
</ref>
<ref id="bib59">
<label>59</label>
<element-citation id="sbref590" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keller</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Kum</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Wehring</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Koola</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>A review of anti-inflammatory agents for symptoms of schizophrenia</article-title>
<source/>J Psychopharmacol
          <volume>27</volume>
<year>2013</year>
<fpage>337</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="pmid">23151612</pub-id>
</element-citation>
</ref>
<ref id="bib60">
<label>60</label>
<element-citation id="sbref600" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solmi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Veronese</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Thapa</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia</article-title>
<source/>CNS Spectr
          <volume>22</volume>
<year>2017</year>
<fpage>415</fpage>
<lpage>426</lpage>
<pub-id pub-id-type="pmid">28181901</pub-id>
</element-citation>
</ref>
<ref id="bib61">
<label>61</label>
<element-citation id="sbref610" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levkovitz</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mendlovich</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Riwkes</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia</article-title>
<source/>J Clin Psychiatry
          <volume>71</volume>
<year>2010</year>
<fpage>138</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="pmid">19895780</pub-id>
</element-citation>
</ref>
<ref id="bib62">
<label>62</label>
<element-citation id="sbref620" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deakin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Suckling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>TRE</given-names>
</name>
</person-group>
<article-title>The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial</article-title>
<source/>Lancet Psychiatry
          <volume>5</volume>
<year>2018</year>
<fpage>885</fpage>
<lpage>894</lpage>
<pub-id pub-id-type="pmid">30322824</pub-id>
</element-citation>
</ref>
<ref id="bib63">
<label>63</label>
<element-citation id="sbref630" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyaoka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yasukawa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hayashida</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Inagaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Horiguchi</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Possible antipsychotic effects of minocycline in patients with schizophrenia</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <volume>31</volume>
<year>2007</year>
<fpage>304</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="pmid">17030375</pub-id>
</element-citation>
</ref>
<ref id="bib64">
<label>64</label>
<element-citation id="sbref640" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahuja</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>BT</given-names>
</name>
</person-group>
<article-title>Possible anti-catatonic effects of minocycline in patients with schizophrenia</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <volume>31</volume>
<year>2007</year>
<fpage>968</fpage>
<lpage>969</lpage>
<pub-id pub-id-type="pmid">17320260</pub-id>
</element-citation>
</ref>
<ref id="bib65">
<label>65</label>
<element-citation id="sbref650" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez Nievas</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Hammerschmidt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kummer</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Terwel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Leza</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Heneka</surname>
<given-names>MT</given-names>
</name>
</person-group>
<article-title>Restraint stress increases neuroinflammation independently of amyloid beta levels in amyloid precursor protein/PS1 transgenic mice</article-title>
<source/>J Neurochem
          <volume>116</volume>
<year>2011</year>
<fpage>43</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">21044080</pub-id>
</element-citation>
</ref>
<ref id="bib66">
<label>66</label>
<element-citation id="sbref660" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Northoff</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>What catatonia can tell us about “top-down modulation”: a neuropsychiatric hypothesis</article-title>
<source/>Behav Brain Sci
          <volume>25</volume>
<year>2002</year>
<fpage>555</fpage>
<lpage>577</lpage>
<pub-id pub-id-type="pmid">12958742</pub-id>
</element-citation>
</ref>
<ref id="bib67">
<label>67</label>
<element-citation id="sbref670" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hadavi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Noyce</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Giovannoni</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Stiff person syndrome</article-title>
<source/>Pract Neurol
          <volume>11</volume>
<year>2011</year>
<fpage>272</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="pmid">21921002</pub-id>
</element-citation>
</ref>
<ref id="bib68">
<label>68</label>
<element-citation id="sbref680" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Alexopoulos</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McMenamin</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome</article-title>
<source/>JAMA Neurol
          <volume>70</volume>
<year>2013</year>
<fpage>1140</fpage>
<lpage>1149</lpage>
<pub-id pub-id-type="pmid">23877118</pub-id>
</element-citation>
</ref>
<ref id="bib69">
<label>69</label>
<element-citation id="sbref690" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scammell</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>Narcolepsy</article-title>
<source/>N Engl J Med
          <volume>373</volume>
<year>2015</year>
<fpage>2654</fpage>
<lpage>2662</lpage>
<pub-id pub-id-type="pmid">26716917</pub-id>
</element-citation>
</ref>
<ref id="bib70">
<label>70</label>
<element-citation id="sbref700" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsutsui</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kanbayashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features</article-title>
<source/>BMC Psychiatry
          <volume>12</volume>
<year>2012</year>
<fpage>37</fpage>
<pub-id pub-id-type="pmid">22569157</pub-id>
</element-citation>
</ref>
<ref id="bib71">
<label>71</label>
<element-citation id="sbref710" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antelmi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pizza</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vandi</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The spectrum of REM sleep-related episodes in children with type 1 narcolepsy</article-title>
<source/>Brain
          <volume>140</volume>
<year>2017</year>
<fpage>1669</fpage>
<lpage>1679</lpage>
<pub-id pub-id-type="pmid">28472332</pub-id>
</element-citation>
</ref>
<ref id="bib72">
<label>72</label>
<element-citation id="sbref720" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gleichman</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>EG</given-names>
</name>
</person-group>
<article-title>Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies</article-title>
<source/>Lancet Neurol
          <volume>7</volume>
<year>2008</year>
<fpage>1091</fpage>
<lpage>1098</lpage>
<pub-id pub-id-type="pmid">18851928</pub-id>
</element-citation>
</ref>
<ref id="bib73">
<label>73</label>
<element-citation id="sbref730" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeSena</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Graves</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Three phenotypes of anti-N-methyl-D-aspartate receptor antibody encephalitis in children: prevalence of symptoms and prognosis</article-title>
<source/>Pediatric Neurology
          <volume>51</volume>
<year>2014</year>
<fpage>542</fpage>
<lpage>549</lpage>
<pub-id pub-id-type="pmid">25070939</pub-id>
</element-citation>
</ref>
<ref id="bib74">
<label>74</label>
<element-citation id="sbref740" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kruse</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lapid</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Lennon</surname>
<given-names>VA</given-names>
</name>
</person-group>
<article-title>Psychiatric autoimmunity: N-methyl-D-aspartate receptor IgG and beyond</article-title>
<source/>Psychosomatics
          <volume>56</volume>
<year>2015</year>
<fpage>227</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">25975857</pub-id>
</element-citation>
</ref>
<ref id="bib75">
<label>75</label>
<element-citation id="sbref750" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>KL</given-names>
</name>
</person-group>
<article-title>Variations of movement disorders in anti-N-methyl-D-aspartate receptor encephalitis: a nationwide study in Taiwan</article-title>
<source/>Medicine (Baltimore)
          <volume>95</volume>
<year>2016</year>
<object-id pub-id-type="publisher-id">e4365
</object-id>
</element-citation>
</ref>
<ref id="bib76">
<label>76</label>
<element-citation id="sbref760" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Granata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matricardi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ragona</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Pediatric NMDAR encephalitis: a single center observation study with a closer look at movement disorders</article-title>
<source/>Eur J Paediatr Neurol
          <volume>22</volume>
<year>2018</year>
<fpage>301</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="pmid">29396169</pub-id>
</element-citation>
</ref>
<ref id="bib77">
<label>77</label>
<element-citation id="sbref770" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herken</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pruss</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients</article-title>
<source/>Front Psychiatry
          <volume>8</volume>
<year>2017</year>
<fpage>25</fpage>
<pub-id pub-id-type="pmid">28261116</pub-id>
</element-citation>
</ref>
<ref id="bib78">
<label>78</label>
<element-citation id="sbref780" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koenig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Duband</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Charmion</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cathebras</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Camdessanche</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Antoine</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Extrapontine myelinolysis of favorable outcome in a patient with autoimmune polyglandular syndrome</article-title>
<source/>Rev Med Interne
          <volume>26</volume>
<year>2005</year>
<fpage>65</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">15639329</pub-id>
</element-citation>
</ref>
<ref id="bib79">
<label>79</label>
<element-citation id="sbref790" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobrynski</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>KE</given-names>
</name>
</person-group>
<article-title>Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes</article-title>
<source/>Lancet
          <volume>370</volume>
<year>2007</year>
<fpage>1443</fpage>
<lpage>1452</lpage>
<pub-id pub-id-type="pmid">17950858</pub-id>
</element-citation>
</ref>
<ref id="bib80">
<label>80</label>
<element-citation id="sbref800" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butcher</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Boot</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: an overview and case series</article-title>
<source/>Am J Med Genet A
          <volume>176</volume>
<year>2018</year>
<fpage>2146</fpage>
<lpage>2159</lpage>
<pub-id pub-id-type="pmid">29777584</pub-id>
</element-citation>
</ref>
<ref id="bib81">
<label>81</label>
<element-citation id="sbref810" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tuzun</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma</article-title>
<source/>Ann Neurol
          <volume>61</volume>
<year>2007</year>
<fpage>25</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="pmid">17262855</pub-id>
</element-citation>
</ref>
<ref id="bib82">
<label>82</label>
<element-citation id="sbref820" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bram</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bubrovszky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Durand</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Lefevre</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Morell-Dubois</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vaiva</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Pernicious anemia presenting as catatonia: correlating vitamin B12 levels and catatonic symptoms</article-title>
<source/>Gen Hosp Psychiatry
          <volume>37</volume>
<year>2015</year>
<fpage>273.e5</fpage>
<lpage>273.e7</lpage>
</element-citation>
</ref>
<ref id="bib83">
<label>83</label>
<element-citation id="sbref830" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jauhar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blackett</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Srireddy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Pernicious anaemia presenting as catatonia without signs of anaemia or macrocytosis</article-title>
<source/>Br J Psychiatry
          <volume>197</volume>
<year>2010</year>
<fpage>244</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="pmid">20807971</pub-id>
</element-citation>
</ref>
<ref id="bib84">
<label>84</label>
<element-citation id="sbref840" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berry</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sagar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Catatonia and other psychiatric symptoms with vitamin B12 deficiency</article-title>
<source/>Acta Psychiatr Scand
          <volume>108</volume>
<year>2003</year>
<fpage>156</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="pmid">12823174</pub-id>
</element-citation>
</ref>
<ref id="bib85">
<label>85</label>
<element-citation id="sbref850" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catalano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Catalano</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Embi</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Embi</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Catatonia. Another neuropsychiatric presentation of vitamin B12 deficiency?</article-title>
<source/>Psychosomatics
          <volume>39</volume>
<year>1998</year>
<fpage>456</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="pmid">9775705</pub-id>
</element-citation>
</ref>
<ref id="bib86">
<label>86</label>
<element-citation id="sbref860" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bharadwaj</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sugaparaneetharan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rajkumar</surname>
<given-names>RP</given-names>
</name>
</person-group>
<article-title>Graves' disease presenting with catatonia: a probable case of encephalopathy associated with autoimmune thyroid disease</article-title>
<source/>Acta Neuropsychiatr
          <volume>24</volume>
<year>2012</year>
<fpage>374</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="pmid">25287181</pub-id>
</element-citation>
</ref>
<ref id="bib87">
<label>87</label>
<element-citation id="sbref870" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urias-Uribe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Valdez-Solis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gonzalez-Milan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ramirez-Renteria</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ferreira-Hermosillo</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Psychosis crisis associated with thyrotoxicosis due to Graves' disease</article-title>
<source/>Case Rep Psychiatry
          <volume>2017</volume>
<year>2017</year>
<object-id pub-id-type="publisher-id">6803682
</object-id>
</element-citation>
</ref>
<ref id="bib88">
<label>88</label>
<element-citation id="sbref880" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saito</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Suwa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yakushiji</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Takezawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Differences in the treatment response to antithyroid drugs versus electroconvulsive therapy in a case of recurrent catatonia due to Graves' disease</article-title>
<source/>Case Rep Psychiatry
          <volume>2012</volume>
<year>2012</year>
<object-id pub-id-type="publisher-id">868490
</object-id>
</element-citation>
</ref>
<ref id="bib90">
<label>90</label>
<element-citation id="sbref900" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shlykov</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rath</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Badger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Winder</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>‘Myxoedema madness’ with Capgras syndrome and catatonic features responsive to combination olanzapine and levothyroxine</article-title>
<source/>BMJ Case Rep
          <volume>2016</volume>
<year>2016</year>
<object-id pub-id-type="publisher-id">bcr2016215957
</object-id>
</element-citation>
</ref>
<ref id="bib91">
<label>91</label>
<element-citation id="sbref910" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lalanne</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Meriot</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Ruppert</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Danion</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Vidailhet</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Attempted infanticide and suicide inaugurating catatonia associated with Hashimoto's encephalopathy: a case report</article-title>
<source/>BMC Psychiatry
          <volume>16</volume>
<year>2016</year>
<fpage>13</fpage>
<pub-id pub-id-type="pmid">26786766</pub-id>
</element-citation>
</ref>
<ref id="bib92">
<label>92</label>
<element-citation id="sbref920" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>PT</given-names>
</name>
</person-group>
<article-title>Severe complication of catatonia in a young patient with Hashimoto's encephalopathy comorbid with Cornelia de Lange syndrome</article-title>
<source/>Kaohsiung J Med Sci
          <volume>31</volume>
<year>2015</year>
<fpage>60</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">25600923</pub-id>
</element-citation>
</ref>
<ref id="bib93">
<label>93</label>
<element-citation id="sbref930" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iskandar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stepanova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Two cases of catatonia with thyroid dysfunction</article-title>
<source/>Psychosomatics
          <volume>55</volume>
<year>2014</year>
<fpage>703</fpage>
<lpage>707</lpage>
<pub-id pub-id-type="pmid">25016358</pub-id>
</element-citation>
</ref>
<ref id="bib94">
<label>94</label>
<element-citation id="sbref940" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrafiat</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Raffin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Deiva</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Catatonia and autoimmune conditions in children and adolescents: should we consider a therapeutic challenge?</article-title>
<source/>J Child Adolesc Psychopharmacol
          <volume>27</volume>
<year>2017</year>
<fpage>167</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="pmid">27093093</pub-id>
</element-citation>
</ref>
<ref id="bib95">
<label>95</label>
<element-citation id="sbref950" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hommer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Longitudinal outcomes of children with pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS)</article-title>
<source/>Eur Child Adolesc Psychiatry
          <volume>27</volume>
<year>2018</year>
<fpage>637</fpage>
<lpage>643</lpage>
<pub-id pub-id-type="pmid">29119300</pub-id>
</element-citation>
</ref>
<ref id="bib96">
<label>96</label>
<element-citation id="sbref960" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swedo</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Garvey</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases</article-title>
<source/>Am J Psychiatry
          <volume>155</volume>
<year>1998</year>
<fpage>264</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="pmid">9464208</pub-id>
</element-citation>
</ref>
<ref id="bib97">
<label>97</label>
<element-citation id="sbref970" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Swedo</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Randomized, controlled trial of intravenous immunoglobulin for pediatric autoimmune neuropsychiatric disorders associated with Streptococcal infections</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <volume>55</volume>
<year>2016</year>
<fpage>860</fpage>
<comment>67.e2</comment>
<pub-id pub-id-type="pmid">27663941</pub-id>
</element-citation>
</ref>
<ref id="bib98">
<label>98</label>
<element-citation id="sbref980" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dell</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <volume>44</volume>
<year>2005</year>
<fpage>1145</fpage>
<lpage>1150</lpage>
<pub-id pub-id-type="pmid">16239863</pub-id>
</element-citation>
</ref>
<ref id="bib99">
<label>99</label>
<element-citation id="sbref990" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bachmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Catatonic syndrome related to acute disseminated encephalomyelitis (ADEM)</article-title>
<source/>Schizophr Res
          <volume>87</volume>
<year>2006</year>
<fpage>336</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="pmid">16733085</pub-id>
</element-citation>
</ref>
<ref id="bib100">
<label>100</label>
<element-citation id="sbref1000" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettingill</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Coebergh</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Antibodies to GABAA receptor alpha1 and gamma2 subunits: clinical and serologic characterization</article-title>
<source/>Neurology
          <volume>84</volume>
<year>2015</year>
<fpage>1233</fpage>
<lpage>1241</lpage>
<pub-id pub-id-type="pmid">25636713</pub-id>
</element-citation>
</ref>
<ref id="bib101">
<label>101</label>
<element-citation id="sbref1010" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nikolaus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Knierim</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Meisel</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Severe GABAA receptor encephalitis without seizures: A paediatric case successfully treated with early immunomodulation</article-title>
<source/>Eur J Paediatr Neurol
          <volume>22</volume>
<year>2018</year>
<fpage>558</fpage>
<lpage>562</lpage>
<pub-id pub-id-type="pmid">29396172</pub-id>
</element-citation>
</ref>
<ref id="bib102">
<label>102</label>
<element-citation id="sbref1020" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petit-Pedrol</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Armangue</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies</article-title>
<source/>Lancet Neurol
          <volume>13</volume>
<year>2014</year>
<fpage>276</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="pmid">24462240</pub-id>
</element-citation>
</ref>
<ref id="bib103">
<label>103</label>
<element-citation id="sbref1030" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Graus</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Antibody-mediated encephalitis</article-title>
<source/>N Engl J Med
          <volume>378</volume>
<year>2018</year>
<fpage>840</fpage>
<lpage>851</lpage>
<pub-id pub-id-type="pmid">29490181</pub-id>
</element-citation>
</ref>
<ref id="bib104">
<label>104</label>
<element-citation id="sbref1040" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCarthy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dineen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Anti-NMDA receptor encephalitis with associated catatonia during pregnancy</article-title>
<source/>J Neurol
          <volume>259</volume>
<year>2012</year>
<fpage>2632</fpage>
<lpage>2635</lpage>
<pub-id pub-id-type="pmid">22752087</pub-id>
</element-citation>
</ref>
<ref id="bib105">
<label>105</label>
<element-citation id="sbref1050" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Consoli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ronen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>An-Gourfinkel</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report</article-title>
<source/>Child Adolesc Psychiatry Ment Health
          <volume>5</volume>
<year>2011</year>
<fpage>15</fpage>
<pub-id pub-id-type="pmid">21569502</pub-id>
</element-citation>
</ref>
<ref id="bib106">
<label>106</label>
<element-citation id="sbref1060" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lejuste</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Neuroleptic intolerance in patients with anti-NMDAR encephalitis</article-title>
<source/>Neurol Neuroimmunol Neuroinflamm
          <volume>3</volume>
<year>2016</year>
<fpage>e280</fpage>
<pub-id pub-id-type="pmid">27606355</pub-id>
</element-citation>
</ref>
<ref id="bib107">
<label>107</label>
<element-citation id="sbref1070" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Glanz</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis</article-title>
<source/>JAMA Psychiatry
          <volume>70</volume>
<year>2013</year>
<fpage>271</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="pmid">23344076</pub-id>
</element-citation>
</ref>
<ref id="bib108">
<label>108</label>
<element-citation id="sbref1080" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>TL</given-names>
</name>
</person-group>
<article-title>Increased serum anti-N-methyl-D-aspartate receptor antibody immunofluorescence in psychiatric patients with past catatonia</article-title>
<source/>PLoS One
          <volume>12</volume>
<year>2017</year>
<object-id pub-id-type="publisher-id">e0187156
</object-id>
</element-citation>
</ref>
<ref id="bib109">
<label>109</label>
<element-citation id="sbref1090" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lennox</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Palmer-Cooper</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Pollak</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study</article-title>
<source/>Lancet Psychiatry
          <volume>4</volume>
<year>2017</year>
<fpage>42</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">27965002</pub-id>
</element-citation>
</ref>
<ref id="bib110">
<label>110</label>
<element-citation id="sbref1100" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollak</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Iyegbe</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kempton</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Neuronal autoantibodies shape symptomatology, cognitive function and brain structure in subjects at ultra-high risk for psychosis</article-title>
<source/>Neurology Psychiatry Brain Res
          <volume>29</volume>
<year>2018</year>
<fpage>19</fpage>
<lpage>20</lpage>
<comment>(abstr).</comment>
</element-citation>
</ref>
<ref id="bib111">
<label>111</label>
<element-citation id="sbref1110" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lancaster</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Martinez-Hernandez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Balice-Gordon</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis</article-title>
<source/>Lancet Neurol
          <volume>10</volume>
<year>2011</year>
<fpage>63</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">21163445</pub-id>
</element-citation>
</ref>
<ref id="bib112">
<label>112</label>
<element-citation id="sbref1120" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Economo</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Encephalitis lethargica</article-title>
<source/>Wien Klin Wochenschr
          <volume>30</volume>
<year>1917</year>
<fpage>581</fpage>
<lpage>585</lpage>
</element-citation>
</ref>
<ref id="bib113">
<label>113</label>
<element-citation id="sbref1130" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reid</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>McCall</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Taubenberger</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Experimenting on the past: the enigma of von Economo's encephalitis lethargica</article-title>
<source/>J Neuropathol Exp Neurol
          <volume>60</volume>
<year>2001</year>
<fpage>663</fpage>
<lpage>670</lpage>
<pub-id pub-id-type="pmid">11444794</pub-id>
</element-citation>
</ref>
<ref id="bib114">
<label>114</label>
<element-citation id="sbref1140" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dale</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Merheb</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pillai</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders</article-title>
<source/>Brain
          <volume>135</volume>
<year>2012</year>
<fpage>3453</fpage>
<lpage>3468</lpage>
<pub-id pub-id-type="pmid">23065479</pub-id>
</element-citation>
</ref>
<ref id="bib115">
<label>115</label>
<element-citation id="sbref1150" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lancaster</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The diagnosis and treatment of autoimmune encephalitis</article-title>
<source/>J Clin Neurol
          <volume>12</volume>
<year>2016</year>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">26754777</pub-id>
</element-citation>
</ref>
<ref id="bib116">
<label>116</label>
<element-citation id="sbref1160" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bien</surname>
<given-names>CG</given-names>
</name>
</person-group>
<article-title>Neuropathology of autoimmune encephalitides</article-title>
<source/>Handb Clin Neurol
          <volume>133</volume>
<year>2016</year>
<fpage>107</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="pmid">27112674</pub-id>
</element-citation>
</ref>
<ref id="bib117">
<label>117</label>
<element-citation id="sbref1170" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corlett</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Honey</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Fletcher</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Glutamatergic model psychoses: prediction error, learning, and inference</article-title>
<source/>Neuropsychopharmacology
          <volume>36</volume>
<year>2011</year>
<fpage>294</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="pmid">20861831</pub-id>
</element-citation>
</ref>
<ref id="bib118">
<label>118</label>
<element-citation id="sbref1180" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kikuta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Polymorphism analysis of the upstream region of the human N-methyl-D-aspartate receptor subunit NR1 gene (GRIN1): implications for schizophrenia</article-title>
<source/>Schizophr Res
          <volume>58</volume>
<year>2002</year>
<fpage>83</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">12363394</pub-id>
</element-citation>
</ref>
<ref id="bib119">
<label>119</label>
<element-citation id="sbref1190" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spatola</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Petit-Pedrol</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Simabukuro</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Investigations in GABAA receptor antibody-associated encephalitis</article-title>
<source/>Neurology
          <volume>88</volume>
<year>2017</year>
<fpage>1012</fpage>
<lpage>1020</lpage>
<pub-id pub-id-type="pmid">28202703</pub-id>
</element-citation>
</ref>
<ref id="bib120">
<label>120</label>
<element-citation id="sbref1200" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Joyce</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>AV</given-names>
</name>
</person-group>
<article-title>Benzodiazepine withdrawal syndromes</article-title>
<source/>N Z Med J
          <volume>92</volume>
<year>1980</year>
<fpage>94</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">6107888</pub-id>
</element-citation>
</ref>
<ref id="bib121">
<label>121</label>
<element-citation id="sbref1210" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gleichman</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis</article-title>
<source/>J Neurosci
          <volume>30</volume>
<year>2010</year>
<fpage>5866</fpage>
<lpage>5875</lpage>
<pub-id pub-id-type="pmid">20427647</pub-id>
</element-citation>
</ref>
<ref id="bib122">
<label>122</label>
<element-citation id="sbref1220" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jezequel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Dupuis</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients</article-title>
<source/>Nat Comm
          <volume>8</volume>
<year>2017</year>
<fpage>1791</fpage>
</element-citation>
</ref>
<ref id="bib123">
<label>123</label>
<element-citation id="sbref1230" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gouzoulis-Mayfrank</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Heekeren</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Neukirch</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers</article-title>
<source/>Pharmacopsychiatry
          <volume>38</volume>
<year>2005</year>
<fpage>301</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="pmid">16342002</pub-id>
</element-citation>
</ref>
<ref id="bib124">
<label>124</label>
<element-citation id="sbref1240" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Paradoxical effects of very low dose MK-801</article-title>
<source/>Eur J Pharmacol
          <volume>537</volume>
<year>2006</year>
<fpage>77</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">16626696</pub-id>
</element-citation>
</ref>
<ref id="bib125">
<label>125</label>
<element-citation id="sbref1250" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice</article-title>
<source/>Psychopharmacology (Berl)
          <volume>177</volume>
<year>2005</year>
<fpage>256</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="pmid">15290006</pub-id>
</element-citation>
</ref>
<ref id="bib126">
<label>126</label>
<element-citation id="sbref1260" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inta</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sartorius</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gass</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>NMDA receptor blockade and catatonia: a complex relationship</article-title>
<source/>Schizophr Res
          <volume>168</volume>
<year>2015</year>
<fpage>581</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="pmid">26255565</pub-id>
</element-citation>
</ref>
<ref id="bib127">
<label>127</label>
<element-citation id="sbref1270" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaves</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Marque</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Trzesniak</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update</article-title>
<source/>Braz J Med Biol Res
          <volume>42</volume>
<year>2009</year>
<fpage>1002</fpage>
<lpage>1014</lpage>
<pub-id pub-id-type="pmid">19855900</pub-id>
</element-citation>
</ref>
<ref id="bib128">
<label>128</label>
<element-citation id="sbref1280" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papadia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hardingham</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>The dichotomy of NMDA receptor signaling</article-title>
<source/>Neuroscientist
          <volume>13</volume>
<year>2007</year>
<fpage>572</fpage>
<lpage>579</lpage>
<pub-id pub-id-type="pmid">18000068</pub-id>
</element-citation>
</ref>
</ref-list>
<ref-list id="fread1">
<title>Uncited Reference</title>
<ref id="bib89">
<label>89</label>
<element-citation id="sbref890" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>House</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Treatment of steroid-resistant hashimoto encephalopathy with misidentification delusions and catatonia</article-title>
<source/>Psychosomatics
          <volume>58</volume>
<year>2017</year>
<fpage>322</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="pmid">28190544</pub-id>
</element-citation>
</ref>
</ref-list>
<sec id="sec1" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p id="para760">
<supplementary-material content-type="local-data" id="ecomp10"><caption><title>Supplementary appendix</title></caption><media xlink:href="mmc1.pdf"></media></supplementary-material>
</p>
</sec>
<ack id="ceack10">
<sec>
<title>Acknowledgments</title>
<p>JPR and GB were supported by National Institute for Health Research (NIHR) academic clinical fellowships. TAP was supported by a clinical research training fellowship grant from the <funding-source id="GS1">Wellcome Trust</funding-source> (number 105758/Z/14/Z). ASD received support from the NIHR Maudsley Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trust and the Institute of Psychiatry, Psychology and Neuroscience, King's College London.</p>
</sec>
</ack>
<ack>
<title>Contributors</title>
<p>The manuscript was planned by JPR, TAP, GB, and ASD. JR did the literature search and drafted the manuscript. TAP, GB, and ASD reviewed the manuscripts, made amendments, and added further references. All authors approved the final manuscript.</p>
</ack>
<ack>
<title>Declaration of interests</title>
<p>We declare no competing interests.</p>
</ack>
</back>
</article>
</pmc-articleset>